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Summary (English)  
 
Pulmonary arterial hypertension (PAH) is a devastating condition defined by the sustained 
elevation of pulmonary vascular resistance that rapidly leads to right heart failure and death 
when left untreated. The pathogenesis of PAH is characterized by vascular remodeling and, 
among others, the dysregulated expression of the bone morphogenetic protein receptor type II 
(BMPR2). Mutations in the gene encoding BMPR2 were identified in more than 70% of 
hereditary PAH cases and, moreover, reduced expression levels of BMPR2 were also found in 
patients with non-genetic PAH and in other forms of pulmonary hypertension (PH) as well as 
in animal models mimicking the disease. The different WHO classes of PH are provided as 
Table 1 within the introduction. It is largely accepted that the loss of BMPR2 represents a key 
event in the pathogenesis of PAH, and, moreover, might constitute a final common pathway 
in other forms of PH by enhancing proliferation and apoptosis resistance of cells surrounding 
the small pulmonary arteries eventually resulting in vascular remodeling. So far, the 
mechanisms leading to reduced expression of BMPR2 remained unclear.  
 
The focus of this PhD thesis was set on the identification of mechanisms that control the 
expression of BMPR2 in PAH. Since microRNAs (miRNAs) have emerged as novel 
repressors of gene expression, it was hypothesized that miRNAs might play a role in the 
modulation of BMPR2. Using a database for computational prediction of miRNA-target 
interactions several miRNAs encoded by the microRNA cluster 17/92 (miR-17/92) were 
retrieved as potential regulators of BMPR2. The first part of my thesis provides evidence that 
the expression of BMPR2 is directly regulated by two miRNAs (miR-17 and miR-20a) 
derived from miR-17/92. Moreover, stimulation experiments in endothelial cells revealed 
increased expression of miR-17/92 by interleukin (IL-) 6, a cytokine involved in the 
pathogenesis of PAH. The context of IL-6, miR-17/92 and BMPR2 was further demonstrated 
by showing that persistent activation of the IL-6 pathway led to repressed protein expression 
of BMPR2.  
Consistent with the hypothesis of a miR-17/92-mediated reduction of BMPR2, a recent study 
showed increased expression of miR-17 and miR-20a in the lungs of PH animals. Therefore, 
to address the pathophysiological relevance of miR-20a in vivo, we investigated whether 
specific inhibition of miR-20a by small antisense RNA oligonucleotides (antagomiRs) could 
restore functional levels of BMPR2 and, in turn, might prevent pulmonary arterial vascular 
remodeling. Presented in the second part of this thesis, we found that antagonizing miR-20a in 
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the hypoxia-induced mouse model for pulmonary hypertension upregulated the expression 
levels of BMPR2 and, moreover, significantly reduced wall thickness and luminal occlusion 
of small pulmonary arteries. Consistently, the proliferation of human pulmonary arterial 
smooth muscle cells in vitro was found to be reduced upon transfection with antagomiR-20a. 
These data emphasize that treatment with antagomiR-20a restores the expression of BMPR2 
in pulmonary arteries and prevents the development of vascular remodeling. Therefore, the 
application of antagomiR-20a could be a promising approach for a causative therapy of PH. 
Apart from BMP signaling, it was shown that the IL-6 signaling cascade significantly 
contributes to the maintenance of the vasculature. Along this line, lung-specific IL-6-over 
expressing transgenic mice spontaneously developed PH accompanied by vasculopathic 
changes. Moreover, the serum concentration of IL-6 was also found to be increased in patients 
with PAH. Regarding the importance of IL-6 and miR-17/92 for PH, we further investigated 
the interplay of miR-17/92 and IL-6 signaling and its impact on an inflammatory model, the 
acute-phase response. In the last part of this thesis, we provide evidence that IL-6 upregulated 
the expression of miR-17/92 in different cell types and that one miRNA derived from miR-
17/92, miR-18a, was a potent activator of IL-6 signaling by targeting an endogenous repressor 
of this pathway. These data reveal for the first time a miRNA mediated positive feedback loop 
of IL-6 signal transduction and thus contribute to the understanding of the complex regulatory 
mechanisms within the signal transduction of IL-6. 
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Zusammenfassung (Deutsch) 
 
Die pulmonale Hypertonie (PH) ist der Überbegriff für verschiedene Krankheitsbilder, welche 
in einer signifikanten Erhöhung des Blutdrucks im Lungenkreislauf resultieren und auf Grund 
des vermehrten rechtsventrikulären Afterloads letztendlich zum Rechtsherzversagen führt. 
Die chronisch Drucksteigerung in der Lungenblutbahn wird im Wesentlichen durch drei 
pathogenetische Ereignisse verursacht: eine Mikrothrombosierung der Gefässbahn, eine 
übermässige Vasokonstriktion, sowie durch einen fibrotischen Gefässumbau („Remodeling“). 
Bei letzterem scheint das Gen BMPR2 (bone morphogenetic protein – Rezeptor Typ II) eine 
entscheidende Rolle zu spielen. In ca. 70% aller Patienten mit einer familären Form der 
pulmonal-arteriellen Hypertonie (PAH) ist das BMPR2-Gen durch DNA-Mutationen 
inaktiviert. Interessanterweise wurde aber auch in nicht-vererbaren Formen der PAH sowie in 
anderen Formen der PH eine verminderte Expression von BMPR2 beschrieben. Auch wenn 
die Rolle von BMPR2 nicht definitiv geklärt ist, so könnte die reduzierte Expression von 
BMPR2 den Gefässumbau im Wesentlichen mitverursachen, da durch den Verlust von 
BMPR2 sowohl die Proliferation als auch die Apoptose-Resistenz von Endothelzellen und 
glatten Gefässmuskelzellen erhöht wird. Die molekularbiologischen Mechanismen, die zu 
einer verringerten Oberflächenexpression von BMPR2 in den nicht vererbaren Formen der PH 
führen, sind jedoch bisher unbekannt. 
 
Der Schwerpunkt meiner Doktorabeit war die Erforschung der Regulation der BMPR2-
Expression im Kontext der PH. Auf Grund von Studien, die eine Inhibierung des 
Translations-Prozesses von BMPR2 während der Entwicklung von PH implizierten, 
untersuchte ich die post-transkriptionale Regulation von BMPR2 durch so genannte 
microRNAs (miRNAs). miRNAs sind kleine, nicht proteinkodierende RNA Moleküle, denen 
ein grosses Potential im Feld der post-transkriptionalen Genregulation zugesprochen wird. 
Mit Hilfe von Computerprogrammen, die Sequenzähnlichkeiten zwischen miRNAs und 
potentiell miRNA-regulierten Genen analysieren, konnte ich den miRNA cluster miR-17/92 
als möglichen Regulator von BMPR2 identifizieren. Weiterführende Experimente bestätigten, 
dass zwei miRNAs (miR-17 und miR-20a) aus dem miR-17/92 cluster direkt und spezifisch 
die Expression von BMPR2 kontrollieren. Desweiteren konnte gezeigt werden, dass nach 
Stimulation von pulmonalen Endothelzellen mit Interleukin (IL)-6, dessen Serumspiegel bei 
PAH-Patienten erhöht ist, die Expression von miR-17/92 erhöht war und dass eine 
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Überaktivierung der IL-6 Signalkaskade zu einer Verminderung der BMPR2-Expression 
führte. 
Um die physiologische Bedeutung von miR-20a für den Krankheitsverlauf der PH zu 
untersuchen, verwendete ich das Mausmodell der Hypoxie-induzierten PH, in dem die 
Expression vom miR-20a gezielt durch die Applikation von komplementären, anti-sense- 
orientierten RNA Molekülen („AntagomiRs“) ausgeschaltet wurde. In dieser Studie konnte 
gezeigt werden, dass die Exposition der Tiere gegenüber chronisch-hypoxischen Konditionen 
zu einer Verringerung der BMPR2-Expression in der Lunge führte. Die Antagonisierung von 
miR-20a konnte dabei die BMPR2-Expression auf das Niveau der normoxischen 
Kontrollgruppe normalisieren. Desweiteren zeigten physiologische Untersuchungen, dass 
sowohl die für PH charkteristische rechtsventrikuläre Hypertrophie als auch der Gefässumbau 
von pulmonalen Arteriolen durch Inhibierung von miR-20a signifikant reduziert wurde. Diese 
Daten untermauern die Hypothese, dass miR-20a ein wichtiger Modulator für die Expression 
von BMPR2 und somit ein entscheidender Faktor im Prozess des Gefässumbaus ist. Daher 
könnten Medikamente, die auf eine Inhibierung von miR-20a abzielen, einen neuen 
vielversprechenden Ansatz zur Behandlung von PH darstellen.    
Im letzten Teil meiner Doktorarbeit untersuchte ich das Wechselspiel von IL-6 und dem miR-
17/92 cluster. Am Modell der hepatischen Akut-Phase-Reaktion, die eine sehr gut 
beschriebene Form der IL-6 Signalkaskade repräsentiert, konnte gezeigt werden, dass 
miR-17/92 Teil eines positiven Feedback-Loops in der Regulation des IL-6-Signalweges ist. 
Insbesondere konnte ich dabei zeigen, dass miR-18a (ein Mitglied des miR-17/92 clusters) die 
Expression von PIAS3, einen Repressor des inflammatorischen IL-6-Signalweges, 
verminderte und somit die hepatische Akut-Phase-Reaktion verstärkte. Diese Daten 
identifizierten einen zuvor unbekannten auf miRNA-basierenden Mechanismus der IL-6 
Signalkaskade und tragen somit dazu bei, die komplexe Regulation der IL-6 
Signaltransduktion besser zu verstehen. 
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 Introduction 
 
1.1. Background 
Pulmonary arterial hypertension (PAH) is a fatal disease characterized by the sustained 
increase in mean pulmonary artery pressure (> 25 mm Hg) that leads to exercise limitations, 
syncope, and, when left untreated, to right heart failure and death (Humbert et al., 2004a)  
With about 2-3 cases per million per year, PAH is defined as a rare disease that may be 
heritable, idiopathic (without identification of known risk factors) or associated with other 
disorders (e. g. collagen vascular diseases, portal hypertension, etc.) (Machado et al., 2009). 
However, by accounting all forms of pulmonary hypertension (PH) as provided in Table 1 
(WHO classes of PH, Dana Point 2008), significant elevation of pulmonary vascular 
resistance represents a clinically important disease. 
                                                                            
  
Table 1. Clinical classification of pulmonary hypertension (reproduced from: Humbert and 
McLaughlin, 2009) 
 
Despite the fact that not all types of PH share a common etiology it is widely accepted that the 
observed increases in vascular resistance are caused by three factors: vasoconstriction, 
microthrombosis in situ and vascular remodeling which mainly affects small pulmonary 
arteries (Humbert et al., 2004b). The different forms of PH thus might share a final common 
pathway within the pathogenesis. The contraction of smooth muscle cells (SMCs) 
surrounding the small arteries is mainly associated with an increased expression of the 
vasoconstrictor endothelin-1 (EDN1) in the vasculature, whereas the release of the 
vasodilators nitric oxide (NO) and prostacyclins (e. g. prostaglandin I2) from endothelial cells 
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(ECs) is reduced (Humbert et al., 2004b). On the other hand, narrowing of the arterial lumen 
can also be caused by coagulation of blood cells (microthrombosis) or by increased 
proliferation of ECs and SMCs leading to a thickened vessel wall (vascular remodeling, 
Figure 1). 
 
 
Figure 1. Artery from the lungs of a patient with PH 
The intimal and the smooth muscle cell layer show a strong increase in size due to vascular 
remodeling and aberrant proliferation (reproduced from: Brock M and Huber LC, Rheuma-
Nachrichten, Rheumaklinik und Insitut für Physikalische Medizin, UniversitätsSpital Zürich, Ausgabe 
Nr. 47, 2008) 
 
The development of modern therapies significantly improved the life expectancy of patients 
suffering from P(A)H. Successfully employed strategies comprise the blocking of the 
endothelin receptors by an antagonist (such as Bosentan, Channick et al., 2001) or the 
inhibition of the phopshodiesterase type 5 enzyme (e. g. by Sildenafil, Prasad et al., 2000), 
which is responsible for the break-down of the vasodilator cyclic guanosine monophosphate 
(cGMP). Despite the improvement in life quality current therapies fail to cure PAH, which is 
probably due to the fact that they primarily target the imbalance between vasoconstrictors and 
vasodilators, whereas the process of vascular remodeling still continues. Therefore, in the last 
years several studies have focused on the process of vascular remodeling in order to 
understand the biological mechanism of this disorder and, hopefully, to reverse the once 
established disease.  
In this regard, human genetic investigations shed new light on the pathogenesis of PAH by 
identifying bone morphogenetic protein receptor type II (BMPR2) as the gene responsible for 
approximately 70% of hereditary PAH and 20% of idiopathic PAH cases (Machado et al., 
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2009). The gene BMPR2 encodes a cell membrane receptor that, upon binding of its ligands 
(bone morphogenetic proteins, BMPs), heterodimerizes with members of the BMP receptor 
type I family, activates Smad transcription factors and finally controls the expression of 
multiple target genes (Davies and Morrell, 2008). The association of BMPR2 gene defects and 
impaired vascular remodeling was supported by animal studies, which showed that BMPR2 
heterozygous mice had increased pulmonary arterial pressure and more muscularized vessels 
in the vasculature, a characteristic of vessel remodeling, when compared to wildtype (WT) 
animals (Beppu et al., 2004). Of interest, alterations in the surface expression of BMPR2 have 
also been described in non-genetic forms of PH (Atkinson et al., 2002) suggesting that 
dysregulation of the expression of BMPR2 is a common feature in the pathogenesis of PH. 
Despite its important role in PH little is known about the biology of BMPR2 gene regulation. 
Therefore, studies investigating the regulation of the expression of BMPR2 in the context of 
vascular remodeling and PH appear to be highly promising. The main focus of my PhD thesis 
was to elucidate mechanisms that control the expression of BMPR2 and to proof the 
physiological significance of these mechanisms in PH. Since the laboratory of Prof. Steffen 
Gay has a strong interest and expertise in the novel field of gene regulation by microRNAs 
(miRNAs), I focused my work on the regulation of BMPR2 by miRNAs.  
In the first part of my PhD thesis, we identified a novel pathway involving the cytokine 
interleukin-6 (IL-6) and the polycistronic miRNA cluster miR-17/92 that tightly controls the 
expression of BMPR2. The physiological impact of this pathway was further proven in an in 
vivo model of PH (i. e. hypoxia-induced PH) and is presented as the second part of this thesis. 
Finally, shown in the last part of my thesis, we elucidated the interplay of IL-6 with 
miR-17/92 and its role in an acute inflammatory process, i.e. the acute-phase response.  
 
1.2. BMPR2 in pulmonary hypertension 
In hereditary PAH, germline mutations in the gene encoding BMPR2 comprise a genetic 
hallmark of the disease (Rabinovitch, 2008). In the human body, BMPR2 is expressed in a 
tissue-specific manner with a prominent expression found on the surface of ECs and SMCs of 
the pulmonary arterial circulation (Atkinson et al., 2002). The gene BMPR2 belongs to the 
transforming growth factor-β (TGF-β) superfamily and expresses a 70-80 kDa trans-
membrane serine-threonine kinase receptor that facilities the binding of BMPs (Miyazono et 
al., 2010). BMPs, originally identified as factors that regulate the formation of bones and 
cartilage, exhibit a broad range of biological functions including the development of kidney, 
muscle, and neurons and vascular homeostasis (Kawabata et al., 1998). The receptor BMPR2 
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typically associates with the ligands BMP-2 and BMP-4, which are released from the 
endothelium, whereas the binding of other BMPs, mainly activins and myostatins, is achieved 
by BMPR2-related receptors (e. g. activin receptor type II, ActR2) (Miyazono et al., 2010). 
For BMP signal transduction, the presence of both receptors, BMPR2 and BMPR1, is 
required. Binding of the ligand initiates the BMPR2-mediated transphosphorylation of the GS 
(glycine and serine-rich) domain of BMPR1. The phosphorylation of the GS domain strongly 
increases the serine-threonine kinase activity of BMPR1 that subsequently leads to the 
phosphorylation of associated R-Smad (receptor-regulated Smad) factors (typically Smad1, 
Smad5 and Smad8). Next, R-Smads interact with common-partner Smads (Co-Smads, 
typically Smad4 in the BMP-2 signaling cascade) to form an oligomeric protein complex. 
This oligomeric Smad complex then translocates to the nucleus, where it associates with a 
variety of transcription factors and coactivators which, eventually, leads to an altered 
transcriptional process of BMP target genes (Hardwick et al., 2008) (Figure 2). 
 
              
Figure 2. BMP signaling pathway 
The schematic illustrates the activation of the BMP signaling cascade which is initiated by binding of 
BMPs to a heterodimeric receptor complex composed of the serine-threonine kinases BMPR1 and 
BMPR2. The BMPR2-mediated activation of BMPR1 triggers phosphorylation and activation of R-
Smad transcription factors (Smad1, Smad5 and Smad8) which, guided by Co-Smads (Smad4), then 
shuttle to the nucleus to activate transcription of target genes. The BMP signaling can be inhibited by 
extracellular antagonists (e. g. noggin) that bind BMPs and thereby suppress the association with the 
receptor complex (reproduced from: Hardwick et al., 2008). 
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To achieve a finely balanced response to BMP stimulation, regulatory factors can interact at 
several levels of the pathway. For instance, the extracellular antagonist noggin binds BMP-4 
with high affinity and thus abolishes the association of BMP-4 with its receptor (Zimmerman 
et al., 1996). Moreover, intracellular inhibitor-Smads (I-Smads, typically Smad6 or Smad7) 
prevent BMP-mediated signaling by decreasing the accessibility of R-Smads to BMPR1 
(Miyazono et al., 2010). BMP signaling in the healthy lung endothelium plays an important 
role in the vascular maintenance by regulating the differentiation, proliferation, and apoptosis 
of ECs and SMCs (Davies and Morrell, 2008). The BMP-2 induced target gene family 
inhibitor of DNA binding (Id), for instance, controls differentiation and proliferation of 
human pulmonary arterial SMCs (Yang et al., 2010).  
PH is characterized by a dysfunctional BMP and TGF-β signaling pathway. On the one hand, 
genetic studies identified frameshift or nonsense DNA mutations in the genes encoding the 
receptors for BMPs (BMPR2) and TGF-β (TGFBR1 and TGFBR2) which cause a rapid 
degradation of the transcripts and thus loss of gene expression (Humbert et al., 2004a). On the 
other hand, reduced expression of BMPR2 and TGFBR2 were also found in patients with 
non-genetic (idiopathic) PAH (Atkinson et al., 2002; Yeager et al., 2001) and in animal 
models mimicking the disease (Takahashi et al., 2006; Morty et al., 2007). There is increasing 
evidence that the observed changes in the proliferation of SMCs which promote the vascular 
remodeling are a consequence of defective Smad signaling caused by the loss of BMPR2 
expression (Yang et al., 2005). The therapeutical potential of BMPR2 to relieve the 
devastating condition of PH was tested in animal studies. In 2007, Reynolds and co-workers 
developed an adenoviral construct comprising the coding sequence of BMPR2 and 
specifically transferred the BMPR2 gene to the lungs of rats (Reynolds et al., 2007). The 
delivery of the BMPR2 gene successfully lowered the pulmonary hypertensive response to 
chronic hypoxia as compared to mock-infected controls. Moreover, by performing in vitro 
experiments, the authors found increased Smad signaling and reduced proliferation of 
BMPR2-transfected ephithelial cells. The authors concluded that restoration of BMPR2 
expression by gene transfer therapy could be a promising tool for treatment of PH (Reynolds 
et al., 2007). In contrast to this study, McMurtry et al. demonstrated that the nebulized 
administration of an adenovirus containing the BMPR2 gene failed to lower the pulmonary 
arterial pressure in the monocrotaline rat model for PH (McMurtry et al., 2007) which might 
be explained by differences in the methodology (gene delivery) and in the animal models used 
in both studies. However, more studies are needed to address the question whether gene 
therapy of BMPR2 protects or reverses the development of PH. 
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Restoration of vascular expression of BMPR2 remains an attractive approach for treatment of 
PH. In this regard, further characterization of the regulation of BMPR2 during the 
pathogenesis of PH is needed to better understand the mechanisms leading to reduced 
vascular expression of BMPR2. The identification of such mechanisms would allow the 
development of novel therapeutical approaches in order to restore functional levels of BMPR2 
and to treat PH. Recent studies focusing on the regulation of BMPR2 in the development of 
PH have observed reduced protein but not mRNA levels of this surface receptor. Takahasi et 
al., for instance, described the expression of BMPR2 in pulmonary arteries of rats under 
normal conditions and after exposure to hypoxic conditions. Thereby, hypoxia was found to 
reduce the expression of BMPR2 on the protein levels, whereas the levels of the 
corresponding mRNA were not affected accordingly (Takahashi et al., 2006). Similarly, in the 
monocrotaline-induced rat model of PH, the expression of the BMPR2 protein was rapidly 
reduced without initial effects on the mRNA levels (Morty et al., 2007).  
These findings suggest a post-transcriptional mechanism for the regulation of BMPR2, such 
as the involvement of miRNAs that bind to their target mRNAs by Watson-Crick-base pairing 
at distinct seed regions and, thus, alter mRNA stability or affect protein translation.  
 
1.3. miRNAs in pulmonary hypertension  
miRNAs comprise a novel class of short non-protein-coding RNA molecules that have 
emerged as novel important regulators of gene expression. Since the first description of 
miRNAs in the nematode C. elegans (Lee et al., 1993) miRNAs were found throughout the 
genomes of animals and plants, indicating the biological significance of these RNA-based 
regulators of gene expression. Up to date, more than one thousand miRNA sequences are 
identified in the human genome (source: www.mirbase.org; Griffiths-Jones et al., 2008) and it 
was suggested that up to one third of the human protein-coding genes is regulated by miRNAs 
through post-transcriptional mechanisms (Lewis et al., 2005). Compared to the accumulating 
knowledge about the function of miRNAs little is known about the biogenesis and the 
regulation of miRNAs processing. In general, the biogenesis of miRNAs is characterized by a 
sequence of four steps: (i) the RNA polymerase (Pol II or Pol III) - mediated transcription; (ii) 
the cleavage of the primary transcript by the RNAse III enzyme Drosha; (iii) the exportin-5 - 
facilitated transport of the precursor (pre) miRNA into the cytoplasm; and (iiii) the final 
processing of the stem-loop shaped - pre-miRNA into its mature length by Dicer (summarized 
in Figure 3, Winter et al., 2009)    
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Figure 3. The pathway of miRNA processing  
As a first step, the genomic region comprising the miRNA sequence is transcribed by the action of the 
RNA polymerase enzymes II or III and folds into a characteristic secondary structure. The primary, 
double-stranded miRNA (pri-miRNA) is then further processed by the RNase III enzyme Drosha 
leading to the formation of the pre-miRNA hairpin. Next, exportin-5 facilitates the transport into the 
cytoplasm where the RNase Dicer cleaves the pre-miRNA to its mature length. One strand of the 
mature miRNA, together with the RNA-binding protein Ago-2, is loaded onto RISC (RNA-induced 
silencing complex). The miRNA strand guides RISC to target mRNAs which are either cleaved, 
deadenylated or blocked in order to repress the translational process. (reproduced from: Winter et al., 
2009) 
 
After the last processing step, one strand of the mature miRNA duplex is loaded onto the 
RNA-induced silencing complex (RISC) which then anneals to the miRNA-targeted mRNA 
to either cleave or block the translation of these targeted transcripts (Bartel, 2004). The 
complementarity of each miRNA to its targets decides which post-transcriptional 
modification is chosen: if there is a sufficient complementary the RISC is likely to catalyze 
the cleavage of the target mRNA; on the other hand, translational inhibition is characterized 
by an imperfect but still suitable pairing of miRNA and mRNA (Hutvagner and Zamore, 
2002). Watson-Crick-base pairing occurs between the 5’ end of miRNA (known as the ‘seed’) 
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and a complementary region within the targeted mRNA, commonly located in the 3’ 
untranslated region (UTR) (Lewis et al., 2003). Interestingly, miRNA-regulated genes tend to 
have longer 3’UTR, whereas house-keeping genes have shorter 3’UTRs, probably to escape 
from miRNA-mediated gene regulation (Stark et al., 2005). Because of the fact that the seed 
region of miRNA comprises only 7-8 nucleotides which theoretically could lead to the 
binding of hundreds of transcripts by only one single miRNA the identification of target genes 
remains challenging (Stark et al., 2003). In the last years new approaches have been 
developed that allow an efficient and fast identification of potential miRNA targets. Beside 
the usage of computer-based miRNA target prediction programs proteomic studies showed 
great potential in identifying miRNA targets and, moreover, demonstrated that one miRNA 
can influence the expression of hundreds genes (Selbach et al., 2008). 
miRNAs have been associated with various biological processes including development, 
differentiation and malignancy (Mendell, 2005). The role of miRNAs in vascular biology was 
first proven by miRNA-depletion studies showing that miRNAs are required for normal blood 
vessel development, vascular integrity and vasoconstriction (Sen et al., 2009). By screening 
the miRNA profile during the development of PH in the lungs of chronic hypoxic or 
monocrotaline-treated rats Caruso and colleagues reported dynamic changes in the expression 
of Dicer and distinct miRNAs (Caruso et al., 2010). In both models used the authors found 
reduced expression of let-7f, miR-30c and miR-22 whereas the levels of miR-322, miR-451 
and miRNAs derived from the polycistronic miRNA cluster miR-17/92, namely miR-17 and 
miR-20a, were upregulated indicating a potential role of these miRNAs in the pathogenesis of 
PH. However, Caruso et al. did not investigate the functional role of these miRNAs (Caruso 
et al., 2010), therefore it remains speculative whether these identified miRNAs are important 
factors in the pathogenesis of PH. Nonetheless, a recent publication provided evidence that 
miRNAs are critical for the development of PAH. Courboulin et al. showed that miR-204 is 
significantly downregulated in human PAH and in animal models for PH thereby contributing 
to the anti-apoptotic phenotypes of SMCs (Courboulin et al., 2011). Moreover, this study 
addressed two important points: on the one hand, Courboulin and colleagues demonstrated 
that miR-204 can be used as a novel biomarker in buffy coat samples of patients with PAH 
and, on the other hand, that administration of synthetic miR-204 relieves the severity of 
monocrotaline-induced PH in rats. Consequently, the authors concluded that miRNAs play a 
role in the pathogenesis of PAH and that therapies altering the expression of miRNAs in vivo 
might represent a novel tool for the treatment of this disease (Courboulin et al., 2011). 
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Decreased BMP signaling represents a common feature of PAH (Morty et al., 2007). In this 
regard, novel data illustrated the interplay of BMP signaling and miRNAs. Davis and 
colleagues, for instance, demonstrated that the induction of a contractile phenotype of 
HPASMC is mediated by miR-21 which in turn is strongly upregulated by TGF-β and BMP 
stimulation (Davis et al., 2008). In addition, further studies provided evidence that the BMP-
related TGF-β signaling can be regulated by miRNAs derived from miR-17/92. Dews et al. 
reported that over expression of miR-17/92 results in reduced gene activation by TGF-β 
(Dews et al., 2010). In more detail, the authors demonstrated a specific knock down of two 
important components of the TGF-β signaling cascade, namely TGFBR2 and Smad4, by 
miR-17/92 which finally blunts TGF-β signaling (Dews et al., 2010).  
Based on the findings that (i) the expression of miR-17/92 is increased in experimental 
models of PH (Caruso et al., 2010) and that (ii) miR-17/92 represses TGF-β signaling (Dews 
et al., 2010) one can postulate an important contribution of miR-17/92 to the altered activity 
of BMP signaling observed during the development of PH. Interestingly, because of its 
polycistronic organization (miR-17/92 encodes in total six different miRNAs: miR-17, 
miR-18a, miR-19a, miR-19b, miR-20a, and miR-92) miR-17/92 is associated with many 
different biological processes including heart and lung development and postnatal 
neovascularization (Bonauer and Dimmeler, 2009). On the molecular level, several 
independent lines of evidences reported that miR-17/92 tightly controls the proliferation and 
survival of several cell lines by targeting the anti-apoptotic gene Bim (Bcl-2-interacting 
mediator of cell death; Xiao et al., 2008) and the cell growth inhibitor p21 (Fontana et al., 
2008). 
Based on these findings, the role of miR-17/92 in the development of PH appeared to be 
promising and was therefore selected as a main subject of my PhD thesis. On the one hand, 
we showed that BMPR2, a key molecule in the pathogenesis of PH (Morrell, 2010), is 
targeted by miR-17/92. On the other hand we provided evidence that the expression of 
miR-17/92 itself is regulated by the cytokine IL-6 and thereby offered a novel link between 
inflammation and the pathogenesis of PH.   
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1.4. Inflammation and Pulmonary Hypertension 
Inflammatory mechanisms appear to significantly contribute to some classes of PH including 
PAH associated with connective tissue diseases and human immunodeficiency virus infection 
as well as monocrotaline-induced PH in rats (Humbert et al., 2004a). Evidence for an 
impaired immunological homoeostasis were also found in some patients suffering from 
idiopathic PAH suggesting a potential role for inflammation in the development of this 
disease. In severe PAH, for instance, infiltrating lymphocytes and macrophages in plexiform 
lesions have been described (Tuder et al., 1994) as well as enhanced expression levels of the 
chemokines RANTES (regulated upon activation normal T cell expressed and secreted; 
Dorfmuller et al., 2002) and fractalkine (Balabanian et al., 2002).  
With regard to PH, the pleiotropic cytokine IL-6, which was found to be associated with a 
large number of disorders including pulmonary vascular diseases (Neurath and Finotto, 2011), 
and its downstream signaling factors such as STAT3 (Signal transducer and activator of 
transcription 3) are of special interest. 
The IL-6 pathway has been intensively studied in the last years and is well described. Briefly, 
upon binding to its cell surface receptor IL-6 activates transcription factors that in turn 
enhance the expression of IL-6 target genes including pro-proliferative factors (e. g. c-Myc) 
and anti-apoptotic molecules (e. g. Bcl-2) (Steiner et al., 2009). In general, the binding of IL-6 
initiates the heterodimerization of the IL-6 receptor, gp80, and the IL-6 signal transducer, 
gp130 (Montero-Julian, 2001). The receptor assembly triggers three sequential 
phosphorylation events that are carried out by the receptor-associated Janus kinases (JAKs): 
(1) transphosphorylation and activation of the JAKs; (2) tyrosine phosphorylation of the 
receptor tails; and (3) phosphorylation of the transcription factor STAT3 at tyrosine residue 
705 (Heinrich et al., 1998a). Phosphorylated and activated STAT3 homodimerizes and 
shuttles to the nucleus where it activates the transcription of IL-6 target genes (Seidel et al., 
1995; the IL-6 / STAT3 pathway is summarized in Figure 4). 
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Figure 4. IL-6 / STAT3 signal transduction pathway 
Upon binding of IL-6 to its receptor the phosphorylation of the receptor-associated JAKs is initiated. 
Subsequent phosphorylation of the receptor tails enables the binding and the activation of the 
transcription factor STAT3, which then dimerizes and shuttles to the nucleus. Phosphorylated STAT3 
binds to IL-6 responsive elements located in gene promoters in order to promote the transcription of 
these genes (reproduced from: Benekli et al., 2003)    
 
Several negative feedback loops antagonize the activation of STAT3 to avoid persistent 
downstream signaling. A well characterized feedback pathway includes the blocking of the 
phosphorylation of STAT proteins by the action of the cytokine-inducible protein family of 
SOCS (Suppressors of Cytokine Signaling) (Krebs and Hilton, 2001). The transcriptional 
activity of STAT3 can further be inhibited either by the blocking of the DNA binding domain 
of STAT3 mediated by PIAS3 (Protein Inhibitor of Activated STAT 3; Chung et al., 1997) or 
by the dephosporylation of activated STAT3 achieved by cytoplasmatic phosphatases (e. g. 
SHP-1 or SHP-2; Benekli et al., 2003)      
Intriguingly, patients with PAH were found to have higher serum levels of the 
proinflammatory cytokines IL-1 and IL-6 as compared to healthy controls (Humbert et al., 
1995) and, moreover, serum levels of IL-6 can be used to predict survival of PAH patients 
(Soon et al., 2010). The impact of IL-6 on the pathogenesis of PH has been intensively 
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investigated in recent years. Two studies showed that ectopic administration of IL-6 is 
capable of inducing a mild form of PH. Golembeski and colleagues demonstrated that 
subcutaneous injections of IL-6 caused an increase of right ventricular pressure in rats under 
normoxic conditions (Golembeski et al., 2005). Consequently, as shown by Steiner et al., 
lung-specific overexpression of IL-6 in transgenic mice was found to enhance the vascular 
resistance and, furthermore, to increase the muscularization of the pulmonary arteries, a 
characteristic feature of PAH (Steiner et al., 2009). Conversely, by performing loss-of-
function experiments Savale et al. showed that IL-6 knock-out mice had reduced right 
ventricular pressure and decreased media thickness of pulmonary vessels after exposure to 
chronic hypoxia as compared to wildtype mice (Savale et al., 2009). These findings 
highlighted a pivotal role of IL-6 in the development of PH and, moreover, introduced two 
potential novel experimental models with high pathogenetic relevance to the human disease. 
Whether IL-6 also plays a role in human PH associated with chronic hypoxia (e.g. patients 
with chronic obstructive pulmonary disease, COPD) and whether IL-6 is upregulated in these 
conditions (for example through hypoxia-responsive elements), however, remains elusive so 
far. It will be also interesting whether the known therapies targeting the IL-6 pathway such as 
Actemra®, an antibody binding to the receptor of IL-6 (Nishimoto and Kishimoto, 2006), is of 
benefit for patients with PH. 
Moreover, a dysregulation of STAT3 signaling indicated by persistent activation of STAT3 
was reported in a study published by Masri and colleagues (Masri et al., 2007). By 
investigating the phosphorylation state of STAT3 in ECs derived from characteristic 
plexiform lesions within pulmonary arteries of patients with idiopathic PAH the authors found 
increased activation of STAT3 when compared to healthy donors. In addition, the enhanced 
STAT3 activity was accompanied by upregulated expression of pro-proliferative and anti-
apoptotic molecules (Mcl-1 and Bcl-2; Masri et al., 2007). The authors concluded that the 
observed phenotype of enhanced cell growth and survival of ECs is strongly associated with 
an abnormal and persistent activation of STAT3 (Masri et al., 2007). The fact that increased 
phosphorylation of STAT3 was mainly detected in plexiform lesions of PAH patients (Masri 
et al., 2007) further indicates a potential link between vascular remodeling and activation of 
STAT3. 
In some cell types it has been shown that BMP-2 signaling induces apoptosis mainly mediated 
by an immediate inactivation of STAT3 (Kawamura et al., 2000). In this regard, one can 
speculate that the loss of BMPR2 as observed in P(A)H leads to increased activation of 
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STAT3 accompanied by enhanced proliferation of endothelial and smooth muscle cells and, 
ultimately, to elevated pulmonary arterial pressure (Mathew, 2010).  
 
1.5. Objectives 
 
The regulation of BMPR2 by microRNAs 
 
The pathogenesis of PH is characterized by vascular remodeling and vasoconstriction 
(Humbert et al., 2004b). In hereditary PAH, mutations in the BMPR2 gene leading to loss of 
expression of BMPR2 comprise a genetic hallmark of the disease (Machado et al., 2009). 
BMPR2 is a cell surface receptor expressed on endothelial and vascular smooth muscle cells 
and mediates the binding of BMP ligands to the cell surface. BMPs were shown to inhibit 
proliferation of smooth muscle cells (Wong et al., 2003), a process which requires the 
presence of BMPR2 (Yu et al., 2008). Thus, it was suggested that the reduced expression of 
BMPR2 might lead to significant alterations in the signaling cascade and, ultimately, to 
vascular remodeling. Of interest, decreased expression of BMPR2 has also been found in non-
genetic forms of PH (Atkinson et al., 2002). The intracellular mechanisms leading to this 
downregulation, however, have not been unraveled so far. 
Studies focusing on the role of BMPR2 in the development of PH have observed reduced 
protein levels of this receptor, whereas the levels of the corresponding mRNA were not 
affected accordingly (Takahashi et al., 2006; Morty et al., 2007). These findings suggest that 
the expression of BMPR2 is regulated by post-transcriptional mechanisms. Since miRNAs 
have emerged as important post-transcriptional regulators of gene expression that alter the 
stability of target mRNAs or affect protein translation, we hypothesized an involvement of 
miRNAs in the regulation of BMPR2.  
In the first part of this PhD thesis, we raised the question whether miRNAs could control the 
expression of BMPR2. Using a miRNA target prediction program (i.e. TargetScan; Lewis et 
al., 2005) we identified the miRNA cluster miR-17/92 as a potential modulator of BMPR2 
expression. Therefore, in the first study, we addressed the following issues: (i) the role of 
miR-17/92 in the post-transcriptional regulation of BMPR2 expression; (ii) the effects of 
inflammatory cytokines (i. e. IL-6) on the expression of miR-17/92; and, (iii) the role of the 
transcription factor STAT3 as a master link between IL-6 and the expression of BMPR2. 
Experiments to study the functional impact of miR-17/92 on BMPR2 were carried out in 
human embryonic kidney (HEK)293 cells that were shown to express functional levels of 
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BMPR2 (Ramos et al., 2006), whereas IL-6 stimulation experiments were performed in 
human pulmonary arterial endothelial cells (HPAEC).  
 
Silencing of miRNAs in an in vivo model of PH 
 
We proposed that miRNAs regulate the expression of BMPR2 and, in the first study, we 
identified a pathway involving the IL-6-inducible transcription factor STAT3 and a 
miR-17/92 derived miRNA, miR-20a (Brock et al., 2009). Our hypothesis of a miR-20a-
mediated downregulation of BMPR2 in PH was further supported by Caruso et al. showing 
that miRNAs encoded by miR-17/92 are overexpressed during the development of PH in the 
lungs of chronic hypoxic or monocrotaline-treated rats (Caruso et al., 2010). Our pathway 
thus might represent a unifying mechanism in the pathogenesis of several forms of PH. 
Consequently, miR-17/92 appeared to be an interesting target for further investigations. 
Regarding the pathogenesis of PH and therapies involving BMPR2 gene delivery (Reynolds et 
al., 2007), our model offered the potential to increase levels of endogenously expressed 
BMPR2 by antagonizing miR-20a. 
The efficient and non-toxic inhibition of miRNAs in vivo is subject of intensive research 
considering that such methods could be used as novel therapeutic approaches to target 
miRNA expression in human disease. In this regard, antagomiRs emerged as promising and 
appropriate tools (Krutzfeldt et al., 2005). AntagomiRs are small anti-sense RNA molecules 
directed against miRNA sequences that are further modified in order to improve their stability 
(methylation of the RNA backbone) and delivery (cholesterol conjugation) (Krutzfeldt et al., 
2005). 
In the second part of my PhD thesis, we investigated feasibility and functional readout of 
specific antagonization of miR-20a by using antagomiRs in a mouse model of hypoxia-
induced pulmonary hypertension. The following issues were addressed: (i) the efficiency of 
miR-20a knock down by intraperitoneal injections of antagomiR-20a; (ii) the functional 
consequence of miR-20a knock down on vascular remodeling and right heart hypertrophy; 
and, (iii) the potential of antagomiR-20a to restore functional expression levels of BMPR2 in 
the lungs of chronic hypoxic mice.  
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miR-17/92 and IL-6 signaling 
 
We provided evidence that the cytokine IL-6 and its downstream signaling factors (i.e. 
STAT3), respectively, regulate the expression of miR-17/92 in pulmonary endothelial cells. In 
addition, we identified a palindromic TT – AA motif with a spacing of four base pairs in the 
promoter of miR-17/92, which indicates the binding of the IL-6-inducible transcription factor 
STAT3. These findings emphasize a potential link between miR-17/92 and inflammatory 
processes (Brock et al., 2009). Since some IL-6-induced target genes contribute to feedback 
loops of IL-6 signaling (e. g. the SOCS genes; Krebs and Hilton, 2001) we hypothesized that 
miR-17/92 might represent a novel player within this signal transduction cascade.  
The hepatic acute-phase response, which represents the systemic reaction to acute 
inflammation and tissue damage, is well characterized and represents one of the most 
important examples of IL-6 signaling (Heinrich et al., 1998b). Since the IL-6-induced acute-
phase response in human hepatoma (HepG2) cells provide an established model for the IL-6 
signaling pathway (Hou et al., 2007), we used these cells to investigate the role of miR-17/92 
in the IL-6 signaling cascade 
In this part of my PhD thesis, we addressed the following issues: (i) the role of miR-17/92 in 
the IL-6 signaling cascade and, in more detail, the impact on the expression of IL-6 
downstream target genes such as the acute-phase genes (e. g. fibrinogen and haptoglobin); (ii) 
the identification of novel miR-17/92 targets within the IL-6 signaling cascade; and, (iii) the 
effect of overexpression of miR-17/92 on the phosphorylation and activation of STAT3.  
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Supplementary information 
 
Expanded materials and methods 
 
Cell culture  
Human embryonic kidney (HEK)293 cells and human hepatocellular carcinoma (HepG2) 
cells were grown in Dulbecco’s minimum essential medium (Gibco-Invitrogen, Basel, 
Switzerland) supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine, 50U/ml 
penicillin/streptomycin, 0.2% Fungizone, and 10mM HEPES (all reagents provided by Gibco-
Invitrogen) at 37°C in a humidified atmosphere of 5% CO2. Human pulmonary artery 
endothelial cells (HPAEC) were purchased from Cascade Biologics (Invitrogen, Basel, 
Switzerland) and were cultured in Medium 200 (Invitrogen) according to the manufacturer’s 
instructions. After an incubation period of 24h in starvation medium (0.5% FCS), 
recombinant human IL-6, VEGF or PDGF were added at a final concentration of 20ng/ml 
each. All growth factors and stimulation agents were purchased from R&D Systems 
(Abingdon, United Kingdom). 
 
Plasmid construction  
For overexpression of the miR-17/92 cluster, genomic DNA encoding miR-17/92 was 
amplified and cloned into pcDNA3.1 + (Invitrogen) between the HindIII and EcoRI 
restriction sites as previously described.1 The following primers were used: sense 5’- AAA 
CTT AAG CTT CTA AAT GGA CCT CAT ATC TTT GAG - 3’; anti-sense 5’- CTG CAG 
AAT TCG AAA ACA AGA CAA GAT GTA TTT ACA C - 3’. The full-length sequence of 
human STAT3 was amplified out of cDNA derived from HepG2 cells and cloned into 
pcDNA3.1 + (Invitrogen) between the HindIII and XhoI restriction sites. The following 
primers were used: sense 5’- AAA CTT AAG CTT GCC GCC ATG GCC CAA TGG AAT 
CAG - 3’; anti-sense 5’- CTA GAC TCG AGT CAC ATG GGG GAG GTA GC - 3’. For 
construction of a constitutively active form of human STAT3, called STAT3-C,2 the amino 
acid residues A661 and N663 were mutated to cysteine, respectively. The following primers 
were used: sense 5’ - CAT GGA TTG TAC CTG CAT CCT GGT GTC TCC ACT G - 3’; 
anti-sense 5’ - CCA GGA TGC AGG TAC AAT CCA TGA TCT TAT AGC - 3’. The correct 
sequence of each insert was confirmed by sequencing.  
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For transfection, HEK293 cells were seeded on 6- or 12-well plates at a density of 5 x 105 
cells per ml in an antibiotic-free medium. The next day, cells were transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.  
 
Real time RT-PCR analysis 
Total RNA was extracted using the RNeasy kit (Qiagen, Basel, Switzerland) according to the 
manufacturer's instructions. Quantification of specific RNA transcripts was performed by 
SYBR Green real-time PCRs, using the ABI Prism 7700 Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). SYBR Green real-time PCR was performed for 
human bone morphogenetic protein receptor type II (BMPR2, sense 5’ - AGC CCA ACA 
GTC AAT CCA ATG - 3’; anti-sense 5’ - GGT TGC GTT CAT TCT GCA TAG - 3’), 
human suppressor of cytokine signaling 3 (SOCS3, sense 5’ - CTG TAC CTG GGT GGA 
TGG AG - 3’; anti-sense 5’ - TGA AAG ATG TCC CGT CTC CT - 3’), human signal 
transducer and activator of transcription (STAT3, sense 5’ - TTC ACT TGG GTG GAG AAG 
GAC A - 3’; anti-sense 5’ - CGG ACT GGA TCT GGG TCT TAC C - 3’) and human 
preliminary transcript of the miR-17/92 cluster (C13orf25, sense 5’ - TTG CTA AGT GGA 
AGC CAG AAG - 3’; anti-sense 5’ - CAT CCA CGT GGC AAA ACA T - 3’). To confirm 
specific amplification by the SYBR Green PCR, a dissociation curve analysis was performed 
for each primer pair, and both non-RT negative controls and water controls were used for 
these analyzes. The amounts of loaded RNA were normalized by using a predeveloped 18S 
ribosomal RNA control kit (Applied Biosystems). Differential gene expression was calculated 
with the threshold cycle (Ct), and relative quantification was calculated with the comparative 
Ct method. 
Quantification of mature microRNA-20a  
Total RNA was extracted using the mirVana miRNA Isolation Kit (Applied Biosystems). 
Mature microRNA-20a was detected by stem-loop reverse transcription followed by SYBR 
Green real-time PCR,3 using the ABI Prism 7700 Sequence Detection System (Applied 
Biosystems). Obtained signals were normalized to the expression of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, sense 5’ - GGG AAG CTT GTC ATC AAT GGA - 3’; 
anti-sense 5’ - TCT CGC TCC TGG AAG ATG GT - 3’). 
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Western blot analysis 
For protein extraction confluent cells were lysed using RIPA buffer (150mM NaCl, 50mM 
Tris-HCl, 250μM EDTA, 5mM NaF, 1% Triton X-100, 1% Deoxycholic acid). Whole-cell 
lysates (40 μg) were separated by 10% SDS-PAGE and the proteins were transferred to 
nitrocellulose or polyvinylidene fluoride membrane, respectively. The following antibodies 
were used for Western blot: anti - human BMPR2 (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA), anti - human STAT3 (R&D Systems), anti - human Phospho-STAT3 
(Tyr705, Cell Signaling Technology Inc., Beverly, MA, USA) and anti - α-Tubulin (Sigma, 
St. Louis, MO, USA). Evaluation of the expression of specific proteins was performed by the 
Alpha Imager Software system (Alpha Innotech, San Leandro, CA, USA) via pixel 
quantification of the electronic image. 
 
Reporter gene assay 
A 1554 bp fragment of the 3’untranslated region (UTR) of BMPR2 was amplified out of 
genomic DNA using the following primer: sense 5’ - TAA TTC TAG AGC ATC ATT TAA 
ACA TGC AGA - 3’; anti-sense 5’ - CGA CTC TAG ACA TCA GTT TGC AAA TTA ATA 
G - 3’. The PCR product was XbaI digested and cloned into the XbaI restriction site of the 
pGL3 control vector (Promega AG, Dübendorf, Switzerland). The correct sequence and 
orientation of the insert was confirmed by sequencing. As negative control, the anti-sense 
construct was used according to Kuhn et al.4 For transfection, HEK293 cells were plated in 
12-well plates at a density of 5 x 105 cells per ml in an antibiotic-free medium. The next day, 
cells were transfected with the pGL3 control 3‘UTR of BMPR2 “sense” or “anti-sense” 
construct (150ng/well, respectively) using Lipofectamine 2000. Moreover, a vector encoding 
for the miR-17/92 cluster (pcDNA miR-17/92, 770ng/well) and a vector for normalisation 
(pRL-SV40, Promega; 80ng/well) were added. For inhibition of endogenous miRNAs, a 
similar protocol was applied with the use of anti-miRs (anti-miR-17-5p, anti-miR-19a, anti-
miR-20a, anti-miR-92, all from Applied Biosystem; 100nM/well) instead of the miR-17/92 
encoding vector. After 24h, the cells were lysed, and luciferase activity was measured using 
the Dual-Luciferase Reporter Assay System (Promega). The values obtained were normalized 
to the activity of Renilla luciferase (pRL-SV40). A 1351 bp fragment of the promoter of 
C13orf25 was amplified from human genomic DNA as previously described5 using the 
following primer: sense 5’ - GGG CTC GAG ATC TTT TCA GAT TTG GCC TTT TAT 
TTT - 3’; anti-sense 5’ - AAT GCC AAG CTT AGG AGA GCT TCG CGG AGG AG - 3’. 
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The PCR product was digested with BglII and HindIII and cloned into the pGL3 basic vector 
(Promega). A mutation was introduced into the STAT3 binding site using the following 
primers: sense 5’ - TAT GTC CTT GAG AAT TCC GGA ATT TCC TG - 3’; anti-sense 5’ - 
TCT CAA GGA CAT AAT TGT TAA AAG TGA GG - 3’ (alterations underlined). The 
correct sequence of each insert was confirmed by sequencing. For transfection, HepG2 cells 
were plated in 12-well plates at a density of 5 x 105 cells per ml in an antibiotic-free medium. 
The next day, cells were co-transfected either with the pGL3 basic promoter of C13orf25 
wildtype (pGL3 basic promoter WT) or with the pGL3 basic promoter of C13orf25 ΔSTAT3 
(pGL3 basic promoter ΔSTAT3, each 140ng/well) and pRL-SV40 (60ng/well) using 
FuGENE6 (Roche Diagnostics AG, Rotkreuz, Switzerland). After 6h, the cells were serum 
starved and stimulated with IL-6 (20ng/ml) for a time period of 4h. Luciferase activity was 
measured as mentioned above.  
 
Nuclear transfection 
To knock down the endogenous expression of the human STAT3 gene validated siRNA for 
STAT3 was purchased from Qiagen (Hs_STAT3_7 HP Validated siRNA). Nuclear 
transfection of HPAEC was achieved by using the nucleofection kit HMVEC-L from Amaxa 
(Amaxa GmbH, Cologne, Germany), according to the manufacturer’s protocol. Briefly, cells 
were resuspended in nucleofection solution at a density of 5x105 cells per 100μl. For each 
transfection, 100μl of cell suspension were mixed with siRNA or scrambled negative control 
to obtain a final concentration of 100nM RNA. The suspension was pipetted into a cuvette 
and pulsed in a Nucleofector device using program S-05. Subsequently, cells were diluted 
with prewarmed medium and transferred into a 6-well plate. Following an incubation period 
of 24h, cells were serum starved and stimulated with the respective stimulation agent. 
 
Statistics 
For statistical analysis, GraphPad Prism Software (GraphPad Software, San Diego, CA, USA) 
was used. To compare samples, the paired or unpaired t-test was applied and a p-value < 0.05 
was considered to be statistically significant. All data are shown as mean ± SD. 
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Supplementary figure 
 
 
Supplementary Figure S1. Over expression of miR-17/92 in HEK293 cells results in time-dependent 
downregulation of BMPR2. 
HEK293 cells were transfected with the pcDNA miR-17/92 vector and protein was collected after 24h, 
48h, 72h and 96h. Maximum effect of transient over expression of the miR-17/92 cluster was observed 
by Western blot analysis after 72h resulting in a decrease of app. 30% of BMPR2 protein.  
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Abstract 
Aims. Dysregulation of the bone morphogenetic protein receptor type 2 (BMPR2) is a 
hallmark feature that has been described in several forms of pulmonary hypertension. We 
recently identified the microRNA miR-20a within a highly conserved pathway as regulator of 
the expression of BMPR2. To address the pathophysiological relevance of this pathway in 
vivo, we employed antagomiR-20a and investigated whether specific inhibition of miR-20a 
could restore functional levels of BMPR2 and, in turn, might prevent pulmonary arterial 
vascular remodeling. 
Methods and results. For specific inhibition of miR-20a, cholesterol modified RNA 
oligonucleotides (antagomiR-20a) were synthesized. The experiments in mice were 
performed by using the hypoxia-induced mouse model for pulmonary hypertension and 
animal tissues were analyzed for right ventricular hypertrophy and pulmonary arterial 
vascular remodeling. Treatment with antagomiR-20a enhanced the expression levels of 
BMPR2 in lung tissues; moreover, antagomiR-20a significantly reduced wall thickness and 
luminal occlusion of small pulmonary arteries and reduced right ventricular hypertrophy. To 
assess BMPR2 signaling and proliferation, we performed in vitro experiments with human 
pulmonary arterial smooth muscle cells (HPASMC). Transfection of HPASMC with 
antagomiR-20a resulted in activation of downstream targets of BMPR2 showing increased 
phosphorylation of Smad5 and activation of Id-1 and Id-2. Proliferation of HPASMC was 
found to be reduced upon transfection with antagomiR-20a. 
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Conclusion. This is the first report showing that miR-20a can be specifically targeted in an in 
vivo model for pulmonary hypertension. Our data emphasize that treatment with 
antagomiR-20a restores functional levels of BMPR2 in pulmonary arteries and prevents the 
development of vascular remodeling.  
 
Introduction 
Vascular remodeling of small pulmonary arteries is, together with vasoconstriction and 
microthrombosis, one of the pathogenetic hallmarks of pulmonary arterial hypertension 
(PAH). However, it is largely unknown what causes vascular remodeling or how it can be 
treated. Genetic mutations of the bone morphogenetic protein receptor type II (BMPR2), a 
member of the transforming growth factor (TGF-) β family expressed on the surface of 
endothelial and vascular smooth muscle cells of the pulmonary arterial circulation, have been 
described in familial and idiopathic PAH 1, 2. Moreover, reduced expression of BMPR2 
without concomitant mutations has also been found in other forms of pulmonary hypertension 
including established animal models of the disease  3, 4, 5. It has been debated controversially 
whether the altered expression of BMPR2 due to mutations or downregulation might have a 
functional readout and, thus, an impact on the pathogenesis of PAH. Two recent studies 
however have underscored the potential role of BMPR2-mediated signaling for vascular 
remodeling 6, 7. Long and coworkers observed that dysfunctional BMPR2/TGF-β signal 
transduction results in altered expression of transcription factors including Smads and Id 
(inhibitor of DNA binding) leading to migration of vascular smooth muscle cells 6. Similar 
findings have been reported by another study showing that heterogeneous mutations of 
BMPR2 are associated with disrupted Smad signaling resulting  
in a pro-proliferative and anti-apoptotic phenotype of pulmonary arterial smooth muscle cells 
7. 
MicroRNAs (miRNAs) comprise a class of small, non-coding RNA molecules that regulate 
gene expression on the post-transcriptional level 8; miRNAs preferentially bind to conserved 
regions in the 3’ untranslated region (UTR) of their target genes and either suppress the 
translation or the mRNA stability of these genes 9. There is a growing body of evidence that 
the abnormal expression of miRNAs modulates human diseases by regulating key molecules 
of apoptosis, proliferation or cell signaling 10. Conversely, efficient and non-toxic inhibition 
of miRNAs in vivo is of particular interest since such methods would offer a therapeutic 
approach to suppress altered miRNA expression in human disease. Krutzfeldt and co-workers 
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recently described the inhibition of miRNAs by the application of small anti-sense RNA 
molecules conjugated with cholesterol called antagomiRs in mice 11.  
We have recently proposed that miRNAs might regulate the expression of BMPR2 and 
identified a phylogenetically conserved pathway involving the action of the signal transducer 
and activator of transcription (STAT)3 and the microRNA cluster miR-17/92, mainly of miR-
20a 12. Others have emphasised this hypothesis by showing that miRNAs derived from miR- 
17/92 are over expressed in experimental pulmonary hypertension in vivo 13 making these 
miRNAs interesting targets for further investigations. With respect to pathogenesis and 
therapy, this model offers the potential to restore functional expression levels of BMPR2 by 
antagonizing distinct miRNAs.  
In the present study, we addressed feasibility and functional readout of specific antagonization 
of miR20-a by using antagomiR in an animal model of hypoxia-induced pulmonary 
hypertension in vivo and in vitro. 
 
Material and methods 
Materials and methods are provided as supplementary information. 
 
Results 
 
Application of antagomiR-20a suppresses miR-20a expression in target tissues 
We recently identified a novel signaling pathway that regulates the expression of BMPR2 
through the action of miR-20a 12. Here we addressed the implications of this pathway in an 
animal model of hypoxia-induced pulmonary hypertension.  The in vivo experiments were 
performed as described in the Methods (Fig. 1a). As shown in Figure 1b, repeated 
intraperitoneal injections of antagomiR-20a significantly downregulated the expression levels 
of miR-20a in lung tissues when assessed by qPCR at day 21. AntagomiR-20a treated animals 
showed an expression level of miR-20a of ∆Ct 3.68 ± 0.58 as compared to ∆Ct 2.31 ± 0.23 in 
normoxic control animals thus resulting in a reduction of 59.3% (p < 0.001). On the other 
hand, no significant changes were observed between normoxic control mice and 
antagomiR_mismatch (antagomiR_MM, ∆Ct 2.46 ± 0.2) or PBS (∆Ct 2.18 ± 0.26) treated 
animals. Similar results were observed for other tissues analyzed, in particular heart and liver 
(data not shown). These data indicate that intraperitoneally injected antagomiRs are not 
subjected to a significant hepatic first-pass effect and, thus, are a feasible approach to inhibit 
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the expression of distinct miRNAs in target tissues including the lungs. The sequences of 
antagomiR-20a and antagomiR_MM are provided in Figure 1c. 
       
Figure 1. AntagomiR-20a suppresses miR-20a expression in vivo.  
A. Study design of the in vivo experiments. 4 groups of 8 animals each were used; 3 groups were 
employed in conditions at 10% oxygen for up to 21 days and were treated with antagomiR-20a (25 
mg/kg), antagomiR_MM or PBS. Injections were performed at day 0, 5 and 12. One group was used 
as normoxic control. B. miR-20a expression as normalized to snoRNA202 is significantly 
downregulated upon treatment with antagomiR-20a in lung tissue; statistical analysis by unpaired t-
test. C. Sequence of antagomiR-20a and of the mismatch control, antagomiR_MM. 
 
AntagomiR-20a prevents the development of hypoxia-induced morphological changes within 
the cardiopulmonary circulation 
Morphometric analyzes were performed to assess the functional and hemodynamic 
consequences of reduced expression levels of miR-20a achieved by the application of 
antagomiR-20a. Representative images of small pulmonary arteries are shown in Figure 2A; 
treatment with antagomiR-20a strongly inhibited the vascular remodeling observed in PBS 
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and antagomiR_MM treated hypoxic animals. Computer-based analysis further quantified the 
occlusion of these vessels to be reduced from 13.47 ± 0.73 and 13.33 ± 0.61 (antagomiR_MM 
and PBS treated animals, respectively) to 7.72 ± 0.93 in antagomiR-20a treated mice (p < 
0.001) or to 1.73 ± 0.48 in normoxic controls (Fig. 2B). Similar effects were observed for the 
thickness of the vessel wall showing a reduction from 1.18 ± 0.06 μM and 1.28 ± 0.15 μM in 
antagomiR_MM and PBS treated animals to 0.96 ± 0.05 μM in antagomiR-20a treated 
animals (0.71 ± 0.04 μM in normoxic controls; Fig. 2C).  
Right ventricular hypertrophy, assessed in Figure 2D, after 10% O2 for 21 days was strongly 
reduced in animals receiving antagomiR-20a when compared to hypoxic mice treated with 
antagomiR_MM or PBS (representative images are shown in Fig. 2D). These results were 
confirmed by calculating heart weight relative to body weight (antagomiR_MM: 0.0061 ± 
0.0006 vs. antagomiR-20a: 0.0056 ± 0.0007, p = 0.091; Fig. 2E) and by the relation of the 
right ventricular to the left ventricular volume (RV/LV + S; antagomiR_MM: 0.25 ± 0.01; 
antagomiR-20a: 0.21 ± 0.01, p<0.001; Fig. 2F), indicating that the right ventricular afterload 
was reduced in antagomiR-20a treated mice as compared to mock-treated hypoxic animals. 
Blood analysis performed at day 21 revealed that hypoxia resulted in erythrocytosis, which 
was most prominent in hypoxic PBS-treated animals (Fig 2G). Whereas significant 
differences were observed between normoxic controls (11.63 ± 0.91 g/dl) and all hypoxic 
groups (20.23 ± 2.04 g/dl for antagomiR-20a, 21.75 ± 1.28 g/dl for antagomiR_MM, and 
23.27 ± 1.31 g/dl for PBS, respectively), differences between antagomiR-20a and 
antagomiR_MM treated animals did not reach statistical significance. 
These data imply that the pathomorphological sequelae of hypoxia on the pulmonary 
vasculature, which lead to the development of pulmonary hypertension and, subsequently, to 
right ventricular hypertrophy, can be prevented by the application of antagomiR-20a.  
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Figure 2. AntagomiR-20a prevents pulmonary arterial vascular remodeling. 
A. Representative images of small pulmonary arteries showing reduced hypoxia-induced remodeling 
of intimal and medial vessel layer upon treatment with antagomiR-20a (second from left), quantified 
by analysis of lung vessel occlusion (B) and thickness of vessel wall (C). Similar findings were 
observed for heart morphometry as shown by representative images revealing reduced right ventricular 
hypertrophy by treatment with antagomiR-20a (D, second from left), heart weight relative to body 
weight (E) and heart hypertrophy (F). Hypoxia-induced erythrocytosis was not affected significantly 
by treatment with antagomiR-20a (G). Statistical analysis by unpaired t-test.  
 
AntagomiR-20a restores functional expression levels of BMPR2 in mice 
Since we hypothesized that the reduced expression levels of BMPR2 observed in pulmonary 
hypertension might be due to targeted inhibition by miR-20a 12, we next investigated whether 
the application of specific antagomiRs to mice increase BMPR2 expression levels, and 
whether restoration of this receptor might have functional implications. As shown in Figure 
3a, the mRNA expression levels of BMPR2 in lung tissue were found to be significantly 
reduced in both hypoxic control groups (antagomiR_MM: ∆Ct 3.36 ± 0.73; PBS: ∆Ct 3.2 ± 
0.41) when compared to normoxic mice (∆Ct 2.61 ± 0.19, p = 0.021 and p = 0.004, 
respectively). Interestingly, mRNA levels of BMPR2 under hypoxic conditions could be 
normalized to the levels observed in normoxic control animals by the application of 
antagomiR-20a (∆Ct 2.68 ± 0.16, Fig. 3a). These findings are further illustrated by 
immunohistochemical analysis using antibodies directed against BMPR2 showing that the 
application of antagomiR-20a increased the expression of BMPR2 on endothelial and smooth 
muscle cells of pulmonary arterioles as compared to antagomiR_MM injected mice (Fig. 3b).  
Similarly, Id-2 and Smad5, two validated signaling elements downstream of the BMPR2 
pathway 14 showed enhanced expression levels in lung tissues of animals treated with 
antagomiR-20a as compared to hypoxic controls (Smad5: antagomiR-20a ∆Ct 3.89 ± 0.2 vs. 
hypoxia PBS ∆Ct 4.16 ± 0.26, p = 0.039, Fig. 3c; Id-2: antagomiR-20a ∆Ct 5.09 ± 0.46 vs. 
hypoxia PBS ∆Ct 5.68 ± 0.52, p = 0.031; Fig 3d). These data suggest that treatment with 
antagomiR-20a increases expression levels of BMPR2 within the pulmonary vasculature and, 
most important, could restore functional BMPR2 signaling.  
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Figure 3. Restoration of functional expression levels of BMPR2 by antagomiR-20a in mice. 
Treatment with antagomiR-20a increased mRNA expression of BMPR2 in lung tissue as shown by 
qPCR (A) and by immunohistochemistry (B, antagomiR-20a treated animals shown in upper panel, 
negative controls in lower panel. Magnification 20fold). Similarly, expression of Smad5 (C) and Id-2 
(D) was significantly increased in lung tissue by treatment with antagomiR-20a. Statistical analysis by 
unpaired t-test.    
 
AntagomiR-20a enhances BMP-2 mediated signaling in vitro 
Upon binding of the ligand BMP-2 to BMPR2, Smad5 is activated by phosphorylation, 
which, in turn, activates the transcription factors Id-1 and -2. Since treatment with antagomiR-
20a upregulated the expression levels of BMPR2 in vivo, we next investigated whether 
antagonization of miR-20a might also enhance the BMP-2 mediated signaling in vitro. We 
thus utilised human pulmonary arterial smooth muscle cells (HPASMC) that were stimulated 
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with BMP-2 for different time periods and found that treatment with antagomiR-20a 
enhanced BMPR2-induced signaling activity, i.e. phosphorylation of Smad5 as compared to 
antagomiR_MM controls (Fig. 4a). Phosphorylation of Smad5 (normalised to Smad5 protein 
levels) was increased in stimulated (e. g. after 15min of BMP-2 stimulation: antagomiR_MM, 
1.53 ± 0.09 vs. antagomiR-20a, 1.83 ± 0.28) as well as in unstimulated conditions 
(antagomiR_MM, 1.11 ± 0.23 vs. antagomiR-20a, 1.61 ± 0.38, Fig. 4a). 
Similar effects were seen for the expression levels of Id-1 and -2, showing an augmentation of 
the BMP-2 mediated induction of gene expression by transfection of antagomiR-20a. As 
shown in Fig. 4b, 1h of BMP-2 stimulation enhanced the mRNA levels of Id-1 in antagomiR-
20a treated cells by 2.65 ± 1.55 fold (as compared to 1.52 ± 0.5 fold in antagomiR_MM 
transfected cells, p = 0.102). After 4h of BMP-2 stimulation Id-1 was significantly more 
induced in HPASMC treated with antagomiR-20a (4 ± 2.28) as compared to control cells (3 ± 
2.14, p = 0.035). The mRNA levels of Id-2, on the other hand, were found to be significantly 
more elevated by BMP-2 stimulation in antagomiR-20a treated HPASMC after 1h only 
(antagomiR_MM: 1.14 ± 0.31 fold, antagomiR-20a: 1.65 ± 0.41 fold, p = 0.02, Fig. 4c). 
Finally, promoter studies were performed to illustrate an enhancement of BMP-2 signaling by 
antagonizing miR-20a. The promoter of Id-1 containing multiple Smad transcription factor 
binding sites 15 was cloned into a luciferase-based reporter gene vector. As shown in Fig. 4e, 
4h of BMP-2 stimulation induced the relative promoter activity of Id-1 by 1.38 ± 0.22 fold in 
antagomiR_MM transfected cells. Interestingly, the increase in promoter activity upon 
stimulation with BMP-2 was significantly more enhanced when cells were transfected with 
antagomiR-20a (1.69 ± 0.22 fold, p=0.016). Conversely, the over expression of miR-20a by 
transfection of small RNA oligonucleotides (mat-miR-20a) reduced the BMP-2 mediated 
induction of the promoter activity of Id-1 (mat-miR_MM: 1.81 ± 0.27 fold; mat-miR-20a: 
1.47 ± 0.35 fold, p = 0.013).  
Note that, Smad5 was predicted to be directly targeted by miR-20a (TargetScan, Whitehead 
Institute for Biomedical Research, www.targetscan.org, 16). Accordingly, the expression of 
Smad5 after silencing of miR-20a in HPASMC was analyzed. As shown in Suppl. Fig. S1, 
transfection of antagomiR-20a significantly increased mRNA levels of Smad5 after 72h, but 
failed to enhance protein levels. Moreover, a reporter gene assay comprising the predicted 
seed match of miR-20a in the 3’ untranslated region (UTR) of Smad5 could not show a direct 
miRNA - mRNA interaction (Suppl. Fig. S1).  
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Figure 4. AntagomiR-20a enhances BMP-2 mediated signaling in vitro. 
A. Smad5 phopshorylation in HPASMC treated with BMP-2 analyzed at different time points (15min, 
30min, 60min) shows increased relative phosphorylation upon transfection with antagomiR-20a as 
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indicated by densitometric analysis (left panel). Expression of Id-1 (B) and Id-2 (C) is significantly 
increased after stimulation with BMP-2 when transfected with antagomiR-20a  (assessed at 1 and 4h). 
Statistics by paired t-test, dashed line indicates unstimulated HPASMC. D. For promoter studies, the 
promoter of human Id-1 was cloned containing multiple Smad transcription factor binding sites (as 
described in Lopez-Rovira et al. 15. E. Reporter gene assay in HepG2 cells. Co-transfection of 
pGL3basic-Id1 and antagomiR_MM or antagomiR-20a. Stimulation with BMP-2 for 4h increased 
response in antagomiR-20a treated cells. F. Conversely, the response to BMP-2 was reduced when 
miR-20a was over expressed.  Statisitics by paired t-test. 
     
Proliferation of vascular smooth muscle cells is reduced upon transfection with 
antagomiR-20a 
Proliferation of pulmonary arterial smooth muscle cells is an essential part of the vascular 
remodeling in pulmonary hypertension; we thus addressed whether transfection with 
antagomiR-20a affects cell viability assessed by the MTT assay as surrogate for proliferation. 
As shown in Figure 5A, cell viability was reduced in antagomiR-20a transfected HPASMC by 
12.9 ± 1.2 % as compared to antagomiR_MM transfected controls (p < 0.001). On the other 
hand, no changes were seen when apoptosis was analyzed (data not shown). AntagomiR-20a 
transfection of HPASMC resulted after 24h in upregulation of the cell cycle inhibitor p21 on 
protein level (Fig. 5B) as well as on mRNA level (1.53 ± 0.43 fold, p = 0.051 Fig. 5C). The 
expression of miR-20a was analyzed in the same samples showing downregulation of miR-
20a in HPASMC by antagomiR-20a treatment (Fig. 5D).   
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Figure 5. Cell proliferation is reduced upon transfection with antagomiR-20a. 
A. MTT assay performed in HPASMC after transfection of antagomiR-20a and antagomiR_MM 
showed significant inhibition of cell growth. Statistics by paired t-test. B. p21 was found to be 
upregulated in antagomiR-20a transfected HPASMC as indicated by Western blot experiments (at 24h 
of antagomiR-20a transfection). C. mRNA levels of p21 were found to be increased in HPASMC 
when miR-20a expression was blocked as assessed by qPCR. Statistics by paired t-test. D. Proof of 
principle. miR-20a levels were found to be reduced upon transfection with antagomiR-20a. 
 
Discussion 
We have recently identified a microRNA-mediated signaling pathway that regulates the 
expression of BMPR2 on human pulmonary arterial endothelial cells 12.  While this pathway 
might explain, at least in vitro, the reduced expression of BMPR2 as observed in several 
forms of pulmonary hypertension, the functional relevance of this pathway was unclear so far. 
In the present study we thus employed an established animal model of pulmonary 
hypertension and found that i) intraperitoneal injection of antagomiR in general is a feasible 
approach to efficiently downregulate distinct miRNAs in target tissues; ii) antagonization of 
miR-20a reduces the hypoxia-induced remodeling of pulmonary arterioles and, subsequently, 
reduces right heart hypertrophy in hypoxic animals; and,  iii), that treatment with antagomiR-
20a restores functional expression levels of BMPR2 both in vivo and in vitro. 
In the present experiments, antagonization of miR-20a significantly reduced the vascular 
remodeling in hypoxic animals as assessed by wall thickness and luminal occlusion of small 
pulmonary arteries.  Thickness of the vessel wall was less prominent than in hypoxic control 
animals, probably due to a lesser grade of muscularization upon reduced proliferation of 
vascular smooth muscle cells in the medial layer. The vascular occlusion of these vessels that 
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is commonly observed in pulmonary hypertension and might result from vasoconstriction, 
proliferation of the intimal and medial layer and the development of plexiform lesions, has 
also been found to be reduced significantly in antagomiR-20a treated animals. Vascular 
occlusion and narrowing of the pulmonary arterial lumen increase pulmonary vascular 
resistance and right ventricular afterload; these alterations result in cardiac hypertrophy and, 
ultimately, right heart failure.  In our experiments, antagomiR-20a treated animals revealed 
significantly less right ventricular hypertrophy than their mock-treated hypoxic controls, 
indicating improved pulmonary arterial hemodynamics in antagomiR-20a treated mice. 
However, since the expression of miR-20a has been antagonized not only in the lungs, it 
remains unclear whether the observed reduction of right ventricular hypertrophy is an indirect 
effect of reduced pulmonary arterial pressure or, alternatively, whether it might be due to 
concomitant inhibition of miR-20a in cardiac myocytes. In contrast to other miRNAs, 
including miR-133 17 , miR-21 18 or miR-27b 19 that also have been antagonized 
experimentally, miR-20a has not been described to be overexpressed in response to cardiac 
stress. With regard to other cell types, treatment with antagomiR-20a did not significantly 
alter the hypoxia-induced polycythemia of erythrocytes, indicating that, at least, no such 
pleiotropic effects by antagonizing miR-20a have occurred on hematopoietic cells.  
We further showed that treatment with antagomiR-20a increased the expression levels of 
BMPR2 in lung tissue, thus confirming indirectly that miR-20a targets the mRNA of BMPR2 
as it was suggested previously by our in vitro data on human pulmonary arterial endothelial 
cells. It has been discussed controversially, whether the observed dysregulation of BMPR2 in 
several forms of pulmonary hypertension might be of pathogenetic relevance. However, 
genetic studies and recent in vitro data suggest that BMPR2 and its downstream signaling 
play an important role in cell proliferation, vascular remodeling and, thus, in the development 
of pulmonary hypertension. For instance, Wong and co-workers showed that the activation of 
the BMPR2 signaling pathway in HPASMC leads to the inhibition of proliferation probably 
due to the induction of the cell cycle repressor p21 20. Our findings are along the line of these 
data and further provide evidence both in vivo and in vitro that a functional BMPR2 signaling 
prevents major vascular remodeling within small pulmonary arteries. In particular, we showed 
that the restoration of BMPR2 expression in lung tissue enhances the expression of Smad5 
and, further downstream, leads to activation of the BMP-2 target Id-2. Similarly, in vitro, 
stimulation of HPASMC with BMP-2 and transfection with antagomiR-20a revealed 
increased BMP-2 signaling as indicated by enhanced promoter activity of Id-1 and 
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upregulated expression levels of Id-1 and -2. Since Smad5 could not be validated as a direct 
target of miR-20a (Suppl. Fig. S1) and, on the other hand, the ratio between phosphorylated 
and unphosphorylated Smad5 was found to be increased in stimulated and antagomiR-20a 
transfected cells, we suggest that the strengthened response of HPASMC to BMP-2 is directly 
due to an antagomiR-20a mediated increase of BMPR2 expression that enhances the 
phosphorylation activity upon binding of BMP-2. The transcription factors Id-1 and -2 have 
been associated with cell proliferation 21; activated Id-1/-2 thus would reduce the proliferation 
rate of cells. Here, levels of Id-1 and -2 have been found to be increased in antagomiR-20a 
treated HPASMC, and, in subsequent experiments, the proliferation of HPASMC was reduced 
by transfection of antagomiR-20a. These data strongly indicate that the restoration of BMPR2 
by treatment with antagomiR-20a is functional and, thus, reconstitutes the downstream 
signaling of BMPR2 in pulmonary arterial smooth muscle cells and in lung tissue. The 
reduced proliferation of smooth muscle cells was further shown to be associated with 
enhanced expression of the cell cycle repressor p21. We suggest that the observed increased 
expression of p21 by antagomiR-20a is caused by two ally acting mechanisms. On the one 
hand it was shown that miR-20a directly regulates the expression of p21 22, and on the other 
hand Wong et al. demonstrated that BMP-2 signaling enhances protein levels of p21 20. 
Therefore, antagomiR-20a treatment increases p21 levels by the inhibition of miR-20a and by 
enhancing BMP-2 signaling, which might result in growth arrest of smooth muscle cells. In 
summary, functional restoration of BMPR2 appears to inhibit the development of hypoxia-
induced vascular remodeling by enhanced intracellular signaling activity and reduced 
proliferation.  
Finally, antagonization of miR-20a, one of the key microRNAs in pulmonary hypertension, 
was successfully achieved in hypoxic mice by repeated intraperitoneal injections. Since 
antagomiRs are employed to a growing extent for antagonization of distinct microRNAs for 
pathogenetic investigations and therapeutic purposes 11,  these findings make antagomiRs to 
interesting tools for several reasons: downregulation of miR-20a was observed in target 
organs behind the liver, a finding that mutually excludes a significant hepatic first-pass effect; 
the effects have been longstanding, thus minimising the need for frequent applications; toxic 
effects have not been observed in terms of well-being of the animals or interferon-gamma 
expression in liver tissue (data not shown). Moreover, to our knowledge, this is the first report 
on intraperitoneal application of antagomiRs. 
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Taken together, we show here for the first time that the development of hypoxia-induced 
changes of small pulmonary arteries can be prevented by the application of antagomiR-20a, 
though it remains speculative whether this treatment would also reverse the once established 
disease. Our in vivo data, however, suggest that antagonization of miR-20a inhibits vascular 
remodeling of pulmonary arteries in patients with pulmonary hypertension and, thus, might 
provide a major impact on our understanding and treatment of this disease. 
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Supplementary information 
 
Material and methods 
 
Animal experiments 
Male mice (BL6) were obtained by the Institute for Veterinary Physiology at the University of 
Zurich. A total of 40 animals was used, 8 of these were employed to adjust dosage and timing 
of the intraperitoneal (i.p.) applications of antagomiR-20a (pre-test). The study design of the 
in vivo experiments is provided in Figure 1a. Four groups were used (n= 8 each): 3 groups 
were employed in hypoxic conditions. The fraction of oxygen was decreased gradually from 
21% to 10% over 60 minutes. Hypoxic conditions were provided by chambers connected to a 
gas mixer (Ruskinn Life Science). Animals were treated with antagomiR-20a (25 mg/kg), 
antagomiR negative control (antagomiR_MM) or PBS, respectively. Injections were 
performed at baseline (day 0) with boosters performed at day 5 and 12. One group of animals 
was used as normoxic controls. Mice were assessed daily for activity and well-being. Food 
and water was provided ad libitum. Blood gas analysis, morphometry and tissue preparation 
for later analysis were performed on day 21. The experiments were approved by Zurich 
Canton’s Veterinary office. To assess morphometry, hearts and lungs were removed and 
stained with hematoxylin and eosin. Parameters including heart hypertrophy, cell wall 
thickness, and vessel occlusion were determined by using the MCID analysis program 7.0 
(InterFocus Imaging, Cambridge, UK).  
 
AntagomiR design 
Cholesterol modified RNA oligonucleotides (antagomiRs) directed against human and murine  
miR-20a (MIMAT0000529) were designed as described ((1)) and synthesized by Microsynth 
(Microsynth, Balgach, Switzerland). As a negative control, twelve point mutations were 
introduced into the miR-20a mature sequence (antagomiR_MM) creating a RNA sequence 
which is not encoded in the murine or human genome. The sequences are the following: 
antagomiR-20a (5’ – CUA CCU GCA CUA UAA GCA CUU UA – 3’), antagomiR_MM (5’ 
– GAC CGU UCA CUA UUA CGA GUC AA – 3’). 
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Cell culture  
Human pulmonary arterial smooth muscle cells (HPASMC) were purchased from Invitrogen 
(Invitrogen AG, Basel, Switzerland) and were grown in supplemented Medium 231 
(Invitrogen). Human hepatocellular carcinoma (HepG2) cells and human embryonic kidney 
(HEK)293 cells were grown in Dulbecco’s modified essential medium (Invitrogen AG, Basel, 
Switzerland) supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine, 50U/ml 
penicillin/streptomycin, 0.2% Fungizone, and 10mM HEPES (all reagents provided by 
Invitrogen) at 37°C in a humidified atmosphere of 5% CO2.  BMP-2 (Invitrogen) was used for 
stimulation experiments of HPASMC and HepG2 cells (20ng/ml medium). 
 
Quantitative real time-PCR (qPCR) analysis 
Total RNA was extracted using the RNeasy kit (Qiagen AG, Hombrechtikon, Switzerland). 
RNA was reverse transcribed by using Random Hexamers and MultiScribe Reverse 
Transcriptase (both from Applied Biosystems, Rotkreuz, Switzerland). Quantification of 
specific RNA transcripts was performed by SYBR Green qPCR, using the ABI Prism 7700 
Sequence Detection System (Applied Biosystems). Sequences of primers used in this study 
are shown in Suppl. Table S1. To confirm specific amplification, a dissociation curve analysis 
was performed. The amounts of loaded RNA were normalised to the expression of 18S RNA 
(Applied Biosystems). Differential gene expression was calculated with the threshold cycle 
(Ct) method (2). 
Quantification of mature miRNAs 
Total RNA was extracted using the miRNeasy miRNA isolation kit (Qiagen). Mature 
microRNA sequences were detected by specific stem-loop primers, reverse transcribed using 
MultiScribe Reverse Transcriptase and quantified by performing SYBR Green qPCR (3). 
Stem-loop primers and amplification primers were designed for miR-20a, snoRNA202, and 
RNU48 (Suppl. Table S1). Obtained signals were normalised to the expression of 
snoRNA202 (murine control) or RNU48 (human control) and specific amplification was 
confirmed by performing dissociation curve analysis.  
 
Western blotting 
For protein extraction, cells were lysed with sample loading buffer (62.5mM TrisHCl pH 6.8, 
2% SDS, 10% glycerol, 5mM β-mercaptoethanol, bromphenolblue). Whole-cell lysates were 
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separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
the proteins were transferred to polyvinylidene fluoride membrane. Membranes were 
incubated with the following primary antibodies: anti - human Smad5, anti - Phospho-Smad5 
(phospho S463 + S465; both from Abcam plc, Cambridge, UK), anti - human p21 (Cell 
Signaling Technology, Danvers, MA, USA), and anti - α-tubulin (Sigma, St. Louis, MO, USA 
or Abcam). Bands were detected with species-specific secondary antibodies coupled to 
horseradish peroxidase (Jackson ImmunoResearch Europe Ltd, Suffolk, UK). Evaluation of 
the expression of proteins was performed by the Alpha Imager software system (Alpha 
Innotech, San Leandro, CA, USA) via pixel quantification of the electronic image. 
 
Plasmid construction 
For promoter studies, a fragment (1247 bp) of the human Id-1 promoter containing Smad 
transcription factor binding sites (4) was amplified from human genomic DNA (Promega AG, 
Dübendorf, Switzerland) using PCR. The PCR product was digested with BglII and HindIII 
and cloned into the firefly luciferase-based pGL3basic vector (Promega). For normalisation of 
the luciferase activity, a modified vector encoding for Renilla luciferase (pRL-SV40, 
Promega) was used: the SV40 promoter of pRL-SV40 was removed by digestion with BglII 
and HindIII and replaced by the promoter of GAPDH (1063 bp). For confirmation of direct 
miRNA - mRNA interactions, the 3’untranslated region (UTR) of human Smad5 (1608 bp) 
was amplified from human genomic DNA using PCR. The obtained PCR product was 
digested with NheI and cloned into the pGL3control vector (Promega). Primer sequences used 
for cloning are shown in Suppl. Table S1. The correct sequence of each insert was confirmed 
by sequencing. 
 
Reporter gene assay 
For promoter activity studies, HepG2 cells were transfected with pGL3basic-Id1 (600ng) and 
pRL-GAPDH (300ng) using Lipofectamine 2000 (Invitrogen). In addition, RNA molecules 
for the inhibition (antagomiR-20a and, as negative control, antagomiR_MM) or for the 
overexpression of miR-20a (mat-miR-20a, sequence 5’ – UAA AGU GCU UAU AGU GCA 
GGU AG – 3’, and as negative control, mat-miR_MM, sequence 5’ – GAC CGU UCA CUA 
UUA CGA GUC AA – 3’) were co-transfected (all 100nM/well). After 48h, the cells were 
stimulated with BMP-2 (20ng/ml) for 4h, harvested, and luciferase activity was measured 
using the Dual-Luciferase Reporter Assay System (Promega). The values obtained were 
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normalised to the activity of Renilla luciferase (pRL-GAPDH). For miRNA target validation, 
HEK293 cells were transfected with pGL3control-Smad5 (150ng) and pRL-SV40, 80ng) 
using Lipofectamine 2000. Moreover, RNA molecules for the inhibition of miR-20a 
(antagomiR-20a and, as negative control, antagomiR_MM) were added. After 24h, the cells 
were lysed, and luciferase activity was measured using the Dual-Luciferase Reporter Assay 
System. The values obtained were normalised to the activity of Renilla luciferase (pRL-
SV40).  
 
Transfection of antagomiRs in vitro 
For specific knock down of miR-20a in HPASMC, antagomiR-20a (100nM) was transfected 
using Lipofectamine 2000. AntagomiR_MM (100nM) served as negative control. Following 
an incubation period of 72h, cells were stimulated with BMP-2 (20ng/ml) for different time 
points (as indicated), harvested, and gene expression analysis was performed.  
Cell viability assay 
To assess cell viability, HPASMC were seeded in 24-well plates and were transfected with 
antagomiR-20a or antagomiR_MM (100nM) using Lipofectamine 2000. After 72h, 100μl of 
Thiazolyl Blue Tetrazolium Bromide solution (MTT, 5mg/ml, Sigma) was added to each well 
and incubated for 7h. Purple MTT formazan crystals were dissolved in acidified isopropanol 
and spectrophotometrically measured at a test wavelength of 560 nm. The measured 
absorbance directly correlates with the viability and the number of cells. 
 
Immunohistochemistry  
To illustrate expression of murine BMPR2 in vivo , formalin-fixed paraffin embedded tissue 
sections were stained with goat - anti - BMPR2 (sc-5682, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA),  developed with 3,3'-diaminobenzidine and counter stained with 
hematoxylin and eosin. Normal goat IgG was used as negative control.   
 
Statistics 
For statistical analysis, GraphPad Prism Software (GraphPad Software, San Diego, CA, USA) 
was used. To compare samples with parametric distribution, the paired or unpaired t-test was 
applied and a p-value < 0.05 was considered to be statistically significant (* p < 0.05, ** p < 
0.01, *** p < 0.001). All data are shown as mean ± SD. 
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Supplementary figures and tables 
 
 
Figure S1. Human Smad5 is not a direct target of miR-20a. 
The expression of miR-20a in HPASMC was blocked by transfection of antagomiR-20a. Treatment 
with antagomiR_MM served as negative control. (A) Inhibition of miR-20a after 72h resulted in 
significantly increased mRNA levels of Smad5 as assessed by qPCR (n = 5). (B) Western blot showed 
no upregulation of Smad5 on protein levels in cells transfected with antagomiR-20a (n = 4). One 
representative Western blot is shown. (C) HEK293 cells were co-transfected with a reporter gene 
vector containing the 3’UTR of Smad5 (illustration is shown) and antagomiR_MM or antagomiR-20a. 
Inhibition of miR-20a by antagomiR-20a did not upregulate relative luciferase activity indicating no 
direct miRNA – mRNA interaction. As a positive control a reporter gene assay containing the 3’UTR 
of BMPR2 (described in Brock et al., (5)) was used (n = 3). Statistical analysis by paired student’s t-
test (antagomiR_MM control transfection was set to 1). 
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Table S1. Primer sequences 
 
gene expression analysis   
    
BMPR2 (mmu) fwd 5’ – CCA CGA GGA GAT CAT TAT AAA CC– 3’ 
BMPR2 (mmu) rev 5’ – ACA TTC CTG CTG TTT AAA TCT CG – 3’ 
Id-2 (mmu) fwd 5’ – CCT TGC AGG CAT CTG AAT TCC – 3’ 
Id-2 (mmu) rev 5’ – GTA CTT TGC TAT CAT TCG ACA TAA G – 3’ 
Smad5 (mmu, hsa) fwd 5’ – AGA GTC CAG TCT TAC CTC CAG – 3’ 
Smad5 (mmu, hsa) rev 5’ – AGG CTG TGT TGT GGA TTG AAT TC – 3’ 
Id-1 (hsa) fwd 5’ – AAG GTG AGC AAG GTG GAG ATT C – 3’ 
Id-1 (hsa) rev 5’ – CAA CTG AAG GTC CCT GAT GTA G – 3’ 
Id-2 (hsa) fwd 5’ – GAA TAA GCG GTG TTC ATG ATT TC – 3’ 
Id-2 (hsa) rev 5’ – GAT TCC GTG AAT TTG TTG TTG TTG – 3’ 
CDKN1A (p21, hsa) fwd 5’ – AGC ATG ACA GAT TTC TAC CAC TC – 3’ 
CDKN1A (p21, hsa) rev 5’ – GGC TTC CTC TTG GAG AAG ATC – 3’ 
    
miRNA expression analysis 
    
miR-20a RT (stem loop 
primer) 
5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA CTG GAT ACG ACT  ACC TG – 3’ 
miR-20a fwd 5’ – GCG GCG GTA AAG TGC TTA TAG TG – 3’ 
miR-20a rev 5’ – TGC AGG GTC CGA GGT AT – 3’ 
RNU48 RT (stem loop 
primer) 
5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC 
GCA CTG GAT ACG ACG GTC AG – 3’  
RNU48 fwd 5’ – CCA TGA GTG TGT CGC TGA TG – 3’ 
RNU48 rev 5’ – GTG CAG GGT CCG AGG T – 3’ 
  
plasmid construction   
    
Id-1 promoter (BglII)    
fwd 
5’ – GGG CTC GAG ATC TTG CAG AGC TGG AAA 
GAG AAC – 3’ 
Id-1 promoter (HindIII) 5’ – AAT GCC AAG CTT AGT GCG GAG CCA CAG 
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rev CTT  –   3’ 
3'UTR of Smad5 (NheI) 
fwd 
5’ – TAA TGC TAG CCA ATT ATA TTG TTA GTG GAC 
TTG – 3’ 
3'UTR of Smad5 (NheI) 
rev 
5’ –  CGA CGC TAG CGA GAG AAG AGT CTA TAT 
TCG  – 3’ 
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Supplementary information 
 
Expanded materials and methods 
 
Cell culture  
Human hepatocellular carcinoma (HepG2) cells and human embryonic kidney (HEK)293 
cells were grown in Dulbecco’s modified Eagle’s medium (Invitrogen AG, Basel, 
Switzerland) supplemented with 10% fetal calf serum (FCS; Invitrogen) at 37°C in a 
humidified atmosphere of 5% CO2. Human primary hepatocytes (n=2) were purchased from 
Lonza (Lonza, Verviers, Belgium) and cultured according to the manufacturer’s instructions. 
One donor was found to have metastatic liver disease with altered cellular response and was 
excluded from analysis; cells were kindly replaced with a novel batch of hepatocytes by 
Lonza. Prior to IL-6 stimulation, HepG2 cells were serum starved for period of 24h (0.5% 
FCS). IL-6 (R&D Systems, Abingdon, United Kingdom) was used as indicated. 
 
Quantitative real time-PCR (qPCR) analysis 
Total RNA was extracted using the RNeasy kit (Qiagen AG, Hombrechtikon, Switzerland). 
RNA was reverse transcribed by using Random Hexamers and MultiScribe Reverse 
Transcriptase (both from Applied Biosystems, Rotkreuz, Switzerland). Quantification of 
specific RNA transcripts was performed by SYBR Green qPCR, using the ABI Prism 7700 
Sequence Detection System (Applied Biosystems). Sequences of primers used for 
amplification of human fibrinogen-γ-chain (FGG), human haptoglobin (Hp), human primary 
transcript of the miR-17/92 cluster (C13orf25), human signal transducer and activator of 
transcription (STAT)3, human protein inhibitor of activated STAT (PIAS)3 are shown in 
Suppl. Table S1. To confirm specific amplification, a dissociation curve analysis was 
performed. The amounts of loaded RNA were normalized to the expression of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) or hypoxanthine phosphoribosyltransferase 1 
(HPRT1). Differential gene expression was calculated with the threshold cycle (Ct) method 
(1). 
 
Quantitative real time-PCR (qPCR) analysis 
Total RNA was extracted using the mirVana (Applied Biosystems) or the miRNeasy miRNA 
isolation kit (Qiagen). Mature microRNA sequences were detected by specific stem-loop 
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primers, reverse transcribed using MultiScribe Reverse Transcriptase and quantified by 
performing SYBR Green qPCR (2). Stem-loop primers and amplification primers were 
designed for miR-18a, miR-19a, miR-20a, and miR-92a (Suppl. Table S1). Obtained signals 
were normalized to the expression of GAPDH or RNU48 and specific amplification was 
confirmed by performing dissociation curve analysis.  
Western blot 
For protein extraction cells were lysed with sample loading buffer. Whole-cell lysates were 
separated by 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and the proteins were transferred to nitrocellulose membrane. Membranes were blocked with 
dry milk and incubated with the following primary antibodies: anti – PIAS3, anti – Hp (both 
from Abcam, Cambridge, UK), anti - STAT3 (R&D Systems), anti – Phospho-STAT3 
(Tyr705, Cell Signaling Technology, Danvers MA, USA), and anti – α-tubulin (Sigma, St. 
Louis, MO, USA). Bands were detected with species-specific secondary antibodies coupled to 
horseradish peroxidase (Jackson ImmunoResearch Europe Ltd, Suffolk, UK). Evaluation of 
the expression of proteins was performed by the Alpha Imager software (Alpha Innotech, San 
Leandro, CA, USA) via pixel quantification of the electronic image. 
 
Plasmid construction 
For promoter studies, a fragment (878 bp) of the Hp promoter containing two STAT3 binding 
sites was amplified from human genomic DNA (Promega AG, Dübendorf, Switzerland) using 
PCR. The PCR product was digested with BglII and HindIII and cloned into the firefly 
luciferase-based pGL3basic vector (Promega). The same cloning strategy was applied for the 
cloning of the promoter of FGG (578 bp, containing one STAT3 binding site) into the 
pGL3basic vector. For normalization of the luciferase activity, a modified vector encoding for 
Renilla luciferase (pRL-SV40, Promega) was used. The SV40 promoter of pRL-SV40 was 
removed by digestion with BglII and HindIII and replaced by the promoter of GAPDH 
(1063 bp). Primer sequences used for cloning are shown in Suppl. Table S1. The correct 
sequence of each insert was confirmed by sequencing. 
For confirmation of direct miRNA - mRNA interactions, the 3’untranslated region (UTR) of 
PIAS3 (924 bp) was amplified from human genomic DNA using PCR. The obtained PCR 
product was digested with NheI and cloned into the pGL3control vector (Promega). As a 
negative control, the anti-sense construct was used (3). In addition, the corresponding miRNA 
seed match located in the 3’ UTR of PIAS3 was specifically mutated by using mutagenesis 
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PCR. The correct sequences and orientation of the inserts were confirmed by sequencing. The 
primer sequences are provided in Suppl. Table S1.  
 
Reporter gene assay 
For promoter activity studies, HepG2 cells were transfected either with pGL3basic-Hp or with 
pGL3basic-FGG (600ng/well) using Lipofectamine 2000 (Invitrogen). In addition, a vector 
for normalization (pRL-GAPDH, 300ng/well) was co-transfected. After 24h, the cells were 
stimulated with IL-6 (20ng/ml) for 4h, harvested, and luciferase activity was measured using 
the Dual-Luciferase Reporter Assay System (Promega). The values obtained were normalized 
to the activity of Renilla luciferase (pRL-GAPDH). 
For miRNA target validation, HEK293 cells were transfected with the pGL3control 3‘UTR 
constructs of PIAS3 (150ng/well) using Lipofectamine 2000. Moreover, a vector for 
normalization (pRL-SV40, 80ng/well) and precursor molecules of miRNAs (negative 
control#1 or pre-miR-18a, both from Applied Biosystems/Ambion; 25nM) were added. After 
24h, the cells were lysed, and luciferase activity was measured using the Dual-Luciferase 
Reporter Assay System. The values obtained were normalized to the activity of Renilla 
luciferase (pRL-SV40).  
 
Transfection of miRNAs 
For specific over expression of miRNAs in HepG2 cells precursor molecules of miRNAs 
were purchased from Applied Biosystems/Ambion (pre-miR-18a, -19a, -20a, -92a). 
Scrambled negative control #1 served as scrambled control. For over expression of the entire 
cluster (cocktail), 25nM of each miRNA was transfected. In addition, 100nM of each miRNA 
was used in single transfection studies. Nuclear transfection of HepG2 (100nM of RNA) was 
achieved by using the cell line nucleofector kit V (Amaxa GmbH, Cologne, Germany). 
Alternatively, HepG2 cells and primary hepatocytes were transfected with the same amount of 
pre-miRNAs using Lipofectamine 2000. For specific silencing of miR-18a HepG2 cells were 
transfected with anti-miR-18a (100nM, Applied Biosystems/Ambion) using cell line 
nucleofector kit V or Lipofectamine 2000. Following an incubation period of 72h, cells were 
stimulated with IL-6 (20ng/ml) for 4h, harvested, and gene expression analysis was 
performed. In addition, promoter activity studies in miRNA over expressing HepG2 cells 
were performed. 
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Gene silencing 
HepG2 cells were transfected with 200nM of small interfering RNA molecules (siRNAs, all 
provided by Qiagen) using cell line nucleofector kit V (AMAXA). AllStars negative control 
siRNA (Qiagen) served as scrambled control. After an incubation period of 48h, cells were 
stimulated with IL-6 (20ng/ml) for 4h, harvested, and gene expression was analyzed. 
Furthermore, promoter studies in siRNA-transfected HepG2 cells were performed. 
 
Enzyme-linked immunosorbent assay (ELISA) 
HepG2 cells and primary hepatocytes were transfected with pre-miRNAs or anti-miRNAs 
(100nM) using Lipofectamine 2000. Following an incubation period of 72h, cells were 
stimulated with IL-6 (20ng/ml) for 8h or 24h and supernatants were collected. Quantitative 
determination of human Hp and FGG was achieved by using commercially available ELISA 
kits (GenWay Biotec Inc, San Diego, CA, USA) according to the manufacturer’s instructions.  
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Figure S1. Over expression of miR-17/92 in transfected HepG2 cells.  
HepG2 cells were transfected with miRNA precursor molecules (pre-miR-18a, -19a, -20a, -92a, and a 
cocktail of all) or scrambled negative control. (A) Stem-loop qPCR was used to quantify levels of 
miR-18a showing a significant upregulation of miR-18a in pre-miR-18a and cocktail transfected 
HepG2 cells (n=4). The same method was applied for quantification of miR-19a (B), miR-20a (C), and 
miR-92a (D) in pre-miRNA transfected HepG2 cells confirming a significant increase of miRNA 
expression, respectively (n=4). The respective scrambled transfection was set to 1. Statistical analysis 
by paired student’s t-test. 
 
 
 
Figure S2. Silencing of miR-18a decreases acute-phase response in HepG2 cells. 
Antagonizing miR-18a expression was achieved by transfection of HepG2 cells with anti-miR-18a 
molecules. (A) Promoter activity of FGG and Hp was assessed by co-transfection of a luciferase-based 
vector system comprising promoter sequence of either FGG or Hp. IL-6 stimulation (20ng/ml) for 4h 
activated the promoter of FGG and Hp in all samples with the silencing of miR-18a reducing the 
activity of luciferase as compared to scrambled transfection (n=6). (B) Stem-loop qPCR was used to 
quantify levels of miR-18a showing a significant downregulation of miR-18a in anti-miR-18a 
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transfected HepG2 cells (n=6). mRNA levels of FGG and Hp after 4h of IL-6 stimulation (20ng/ml) 
were found to be reduced in anti-miR-18a treated cells compared to scrambled transfection (n≥5). (C) 
Protein levels of fibrinogen and Hp in the supernatants of anti-miR-18a transfected HepG2 cells were 
quantified by ELISA. Release of fibrinogen after 8h of IL-6 stimulation (20ng/ml) was decreased in 
cells transfected with anti-miR-18a as compared to scrambled transfection. The same supernatants 
were assessed for quantification of Hp protein levels and showed significantly decreased secretion of 
Hp when miR-18a was blocked (n=6). (D) Western blot experiments showed increased expression of 
PIAS3 protein levels in anti-miR-18a transfected HepG2 cells confirming the regulation of PIAS3 by 
miR-18a (n=5). Statistical analysis was performed by using the student’s t-test (unpaired for A, B, D 
and paired for C). 
 
 
 
Figure S3. Expression of PIAS3 is reduced after IL-6 stimulation.  
RNA levels of FGG, Hp, PIAS3, and C13orf25 were measured in HepG2 cells stimulated with IL-6 
(20ng/ml). (A) mRNA levels of FGG and (B) Hp were found to be enhanced in a time-dependent 
manner by IL-6 stimulation, whereas the expression of (C) PIAS3 was significantly downregulated at 
24h of IL-6 treatment (0.89±0.09 fold, p=0.036) (n≥5). (D) The expression of the primary transcript of 
miR-17/92 (C13orf25) was significantly induced at 1h of IL-6 treatment (1.22±0.17 fold, p=0.001) 
(n≥5). The correlation of PIAS3 and C13orf25 is deferred probably due to the miRNA maturation 
process (4). The dashed line indicates unstimulated control and was set as 1. Statistical analysis by 
paired student’s t-test. 
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Table S1. Primer sequences 
 
gene expression analysis   
    
GAPDH fwd 5’ – GGG AAG CTT GTC ATC AAT GGA – 3’ 
GAPDH rev 5’ – TCT CGC TCC TGG AAG ATG GT – 3’ 
HPRT1 fwd 5’ – ATG GAC AGG ACT GAA CGT CTT G – 3’ 
HPRT1 rev 5’ – GGC TAC AAT GTG ATG GCC TC – 3’ 
FGG fwd 5’ – TAT TAC CAA GGT GGC ACT TAC TC – 3’ 
FGG rev 5’ – CAT TAT CAT AAC CAT TAG GAG TAG ATG – 3’ 
Hp fwd 5’ – TCA CGG ATA TCG CAG ATG ACG – 3’ 
Hp rev 5’ – CAC ATA GCC ATG TGC AAT CTC G – 3’ 
C13orf25 fwd 5' – TTG CTA AGT GGA AGC CAG AAG – 3' 
C13orf25 rev 5' – CAT CCA CGT GGC AAA ACA T – 3' 
PIAS3 fwd 5' – GAT TCT TAC ATC CAG AGA GGT TC – 3' 
PIAS3 rev 5' – ACC TGT ATG GTA TAA TCA CAT TTG G – 3' 
STAT3 for 5' – TTC ACT TGG GTG GAG AAG GAC A – 3' 
STAT3 rev 5' – CGG ACT GGA TCT GGG TCT TAC C – 3' 
    
miRNA expression analysis 
    
miR-18a RT (stem 
loop primer) 
5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACC TAT CT – 3’ 
miR-18a fwd 5’ – GGC GGT AAG GTG CAT CTA GT – 3’ 
miR-18a rev 5’ – GTG CAG GGT CCG AGG T – 3’ 
miR-19a RT (stem 
loop primer) 
5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACT CAG TT – 3’ 
miR-19a fwd 5’ – CGG CGG TGT GCA AAT CTA TGC  – 3’ 
miR-19a rev 5’ – GTG CAG GGT CCG AGG T – 3’ 
miR-20a RT (stem 
loop primer) 
5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACT  ACC TG – 3’ 
miR-20a fwd 5’ – GCG GCG GTA AAG TGC TTA TAG TG – 3’ 
miR-20a rev 5’ – TGC AGG GTC CGA GGT AT – 3’ 
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miR-92a RT (stem 
loop primer) 
5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACA CAG GC – 3’ 
miR-92a fwd 5’ – CGG CGG TAT TGC ACT TGT CCC – 3’ 
miR-92a rev 5’ – GTG CAG GGT CCG AGG T – 3’ 
RNU48 RT (stem 
loop primer) 
5’ – GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA 
CTG GAT ACG ACG GTC AG – 3’ 
RNU48 fwd 5’ – CCA TGA GTG TGT CGC TGA TG – 3’ 
RNU48 rev 5’ – GTG CAG GGT CCG AGG T – 3’ 
    
plasmid 
construction   
    
FGG promoter    
fwd 
5’ – GGG CTC GAG ATC TTG AGA AGT GAG AGC CTA TG 
– 3’ 
FGG promoter      
rev 5’ – AAT GCC AAG CTT TGT AAG CTC CTG GGA TAG – 3’ 
Hp promoter        
fwd 
5’ – GGG CTC GAG ATC TGT TGA TGG GCA TTT GTC TTG 
– 3’ 
Hp promoter rev 5’ – AAT GCC AAG CTT GTT GGT CTT GCC TCT GG – 3’ 
GAPDH promoter 
fwd 
5’ – GGG CTC GAG ATC TAC CTG TTC CCA CCG TGT G – 
3’ 
GAPDH promoter 
rev 5’ – AAT GCC AAG CTT AGG CGG TGA CTC GGA CC – 3’ 
3'UTR of PIAS3 
fwd 5’ – TAA TGC TAG CGT TCC CTG GAT TAT GGA AAC – 3’ 
3'UTR of PIAS3  
rev 
5’ – CGA CGC TAG CGA ACA TTC ACA ACC TTT ATT ATG 
– 3’ 
3'UTR of PIAS3 
mut fwd 5’ – CTG CAT TGG TCC AGG GAG GTG GAA G – 3’ 
3'UTR of PIAS3 
mut rev 5’ – CTG GAC CAA TGC AGA ATG AGC CAG G – 3’ 
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5. Discussion and outlook 
 
5.1. The regulation of BMPR2 by microRNAs 
In the first part of this thesis, we found that (i) the expression of BMPR2 is regulated by the 
miR-17/92 cluster on a post-transcriptional level; (ii) this effect is mainly driven by miR-20a; 
(iii) IL-6 increases the expression of miR-17/92 in HPAECs; (iv) the promoter region of 
C13orf25 contains a functional STAT3 binding site; and, finally, (v) persistent activation of 
STAT3 leads to increased expression of miR-17/92, which, in turn, reduces the expression of 
BMPR2.  
The loss of BMPR2 expression is a common feature of PH (Morrell, 2010) and it is believed 
that the observed change in the proliferation of SMCs which promotes the vascular 
remodeling in PH is a consequence of the reduced BMPR2 expression (Yang et al., 2005). 
However, the molecular mechanisms leading to this downregulation of BMPR2 expression 
have not been unraveled so far. Previous studies, however, suggested a post-transcriptional 
mechanism of regulation and, in particular, the contribution of miRNAs. For identification of 
miRNAs potentially involved in the regulation of BMPR2 we performed a computational 
screening revealing multiple miRNA binding sites in the 3’UTR of BMPR2. Because of a 
strong prediction indicated by a high degree of complementarity of the miRNA and its target 
sequence, we decided to investigate whether miR-17/92 could regulate BMPR2 gene 
expression. Indeed, we found a phylogenetically conserved signaling mechanism involving 
IL-6 and miR-17/92 that could provide evidence for a common pathway in the pathogenesis 
of various distinct forms of PH, all of them characterized by loss of BMPR2 expression.  
In animal models of PH the expression of miR-17/92 was found to be significantly increased 
(Caruso et al., 2010), and reduced expression of BMPR2 was described in the same animal 
models (Takahashi et al., 2006; Morty et al., 2007). Consequently, these findings support our 
hypothesis of a miR-17/92-mediated downregulation of BMPR2 in PH. The expression levels 
of miR-17/92 in patients with PH, however, have not been addressed so far. Future work is 
needed to investigate whether the expression of miR-17/92 is dysregulated in the pulmonary 
endothelium of patients suffering from PH. In this regard, it would be interesting to analyze 
miR-17/92 levels in serum samples and its potential as a biomarker for onset and severity of 
PH. Since the screening also revealed other miRNAs as potential regulators of BMPR2, 
including miR-21, miR-25 and miR-153, one might focus further studies on several miRNAs 
that could potentially be employed as biomarkers of this disease.  
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In our study we provided evidence that BMPR2 is regulated by miR-17/92. Consistent with 
these data, TGFBR2, another receptor belonging to the TGF-β superfamily, is also regulated 
by the miR-17/92 cluster (Dews et al., 2010). TGFBR2 mediates apoptosis of ECs and SMCs 
and has been associated with the pathogenesis of PH (Eickelberg and Morty, 2007). 
Therefore, miR-17/92 appears to act as a potent repressor of TGF-β and BMP signaling and, 
thus, might contribute to altered apoptosis resistance and, eventually, to the remodeling of 
pulmonary arterial vessels. 
In our study, the impact of IL-6 on the expression of miR-17/92 was also addressed revealing 
increased expression of miR-17/92 upon IL-6 stimulation. In addition, we identified a 
functional STAT3 binding site in the promoter of miR-17/92. STAT3 is the major mediator of 
IL-6 signaling and was found to be persistently activated in plexiform lesions in severe PH 
(Masri et al., 2007). By transfecting a constitutively active form of STAT3 we found 
increased levels of miR-17/92 and decreased expression of BMPR2 demonstrating a 
functional link of STAT3 signaling and the expression of BMPR2. Thus, our study shed new 
light on the regulation of BMPR2 by inflammatory signals.     
In summary, this was the first time that miRNAs have been associated with PH and, 
moreover, our findings offered for the first time a mechanistic explanation for the 
downregulation of BMPR2 which has been repeatedly described as important feature in the 
pathogenesis of PH. 
 
5.2. The role of miR-20a in an in vivo model of PAH 
Since we assessed the miR-17/92-mediated regulation of BMPR2 in an in vitro model without 
conclusions on the functional relevance of this pathway in vivo, we employed an established 
animal model of PH (exposure to chronic hypoxia) to investigate the physiological role of 
miR-20a in the second part of this thesis. Briefly, we found that (i) intraperitoneal injections 
of antagomiR-20a are a feasible approach to efficiently silence the expression of miR-20a in 
target tissues in a non-toxic manner; (ii) antagonization of miR-20a reduces the hypoxia-
induced remodeling of pulmonary vessels and, subsequently, reduces right heart hypertrophy 
in hypoxic mice; and, (iii) treatment with antagomiR-20a restores expression levels of 
BMPR2 in lung tissues of hypoxic animals. 
Vascular remodeling and occlusion of vessels is commonly observed in pulmonary 
hypertension and results from vasoconstriction and proliferation of the intimal and medial 
layer (Humbert et al., 2004a). By antagonization of miR-20a vascular remodeling in hypoxic 
animals was significantly decreased as assessed by wall thickness and occlusion of small 
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pulmonary vessels. Narrowing of the pulmonary arterial lumen increases vascular resistance 
that results in cardiac hypertrophy and, ultimately, right heart failure. AntagomiR-20a treated 
mice revealed significantly less right ventricular hypertrophy as compared to the mock-treated 
hypoxic control group indicating reduced vascular resistance. Consequently, this study 
showed that miR-20a contributes to the development of hypoxia-induced vascular remodeling 
of the small pulmonary arteries. We showed that, by treatment with antagomiR-20a, the 
development of PH can be prevented. However, it remains unclear at the moment whether the 
application of antagomiR-20a can also reverse established disease. 
Exposure to chronic hypoxia was found to reduce the expression levels of BMPR2 (Takahashi 
et al., 2006). Consistently, we demonstrated that hypoxia decreased mRNA expression of 
BMPR2 in the mock-treated mice. Of interest, the expression of BMPR2 under hypoxic 
conditions could be restored and normalized to the levels measured in normoxic control mice 
by antagonizing miR-20a. These data indicated that miR-20a is an endogenously expressed 
repressor of BMPR2 expression and, thus, further support our hypothesis of a miR-17/92-
mediated regulation of BMPR2. In this regard, it would be of interest to analyze the 
expression of other validated miR-17/92 targets such as TGFBR2 in order to underpin the role 
of miR-17/92 as a master regulator of TGF-β and BMP signaling pathway. Moreover, since 
we showed a functional link of STAT3 and the expression of BMPR2, investigating the 
influence of antagomiR-20a on the expression and activity of STAT3 would be of particular 
interest. 
An attractive hypothesis is that vascular remodeling might be driven by dysregulated 
proliferation and apoptosis resistance (Humbert et al., 2004a). Since we found less vascular 
remodeling in mice treated with antagomiR-20a, we assessed proliferation of HPASMC in 
vitro and found that antagomiR-20a significantly reduced their viability. We suggest that the 
observed decrease in proliferation is caused by two mechanisms. First, it was shown that 
antagonization of miR-20a leads to upregulation of the cell growth inhibitor p21 (Inomata et 
al., 2009), and, second, the activation of the BMP signaling pathway, which is enhanced upon 
transfection of antagomiR-20a, was shown to inhibit proliferation of SMCs (Wong et al., 
2003). Whether silencing of miR-20a can also alter apoptosis or growth of other cells 
involved in the remodeling of the small pulmonary arteries (e. g. ECs) has to be elucidated by 
further studies.    
Taken together, we reported that downregulation of BMPR2 gene expression and the 
development of hypoxia-induced changes of small pulmonary arteries can be prevented by the 
application of antagomiR-20a. 
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5.3. miR-17/92 signaling in acute-phase response 
In the last part of this PhD thesis, we could show that miR-17/92 comprise a novel positive 
feedback loop of the IL-6 – STAT3 signaling cascade. Briefly, we found that IL-6 stimulated 
the expression of miR-17/92 in HepG2 cells and primary hepatocytes and that overexpression 
of one member of miR-17/92, namely miR-18a, significantly increased the IL-6-induced 
response in these cells. On the molecular level, we identified the STAT3 inhibitor PIAS3 as a 
novel direct target of miR-18a. 
Based on the findings of our previous work, we suggested that miR-17/92 is an important 
player in the IL-6 signaling cascade and might contribute to the regulation of STAT3 activity. 
By employing STAT3-inducible reporter gene assays we demonstrated that miR-18a 
significantly increased the transcriptional activity of STAT3. These findings were further 
confirmed by showing an enhanced IL-6-induced acute-phase response in hepatocytes upon 
transfection of miR-18a. Since miRNAs exclusively act as repressors of gene expression 
(Bartel, 2004), we hypothesized that miR-18a represses a negative regulator of IL-6 signaling. 
Consequently, we identified PIAS3, which interferes with the DNA binding activity of 
STAT3 (Chung et al., 1997), as a novel direct target of miR-18a.  
In addition, overexpression of miR-18a also led to increased expression and phosphorylation 
of STAT3. Since PIAS3 blocks the DNA binding of STAT3, we suggested a PIAS3-
independent and additional effect of miR-18a on STAT3. However, the precise mechanism 
leading to increased expression and activity of STAT3 by miR-18a remains unclear at the 
moment. In this regard, we also found increased expression of STAT3 in miR-20a-transfected 
HepG2 cells (unpublished data) suggesting that miR-20a as well as miR-18a is a potent 
regulator of STAT3 gene expression. However, miR-20a failed to stimulate the release of 
acute-phase proteins from IL-6 stimulated HepG2 cells. We suggest that the observed failure 
of increased acute-phase protein secretion by miR-20a is due to the fact that miR-20a might 
target not only repressors but also activators of the IL-6 signaling cascade, for example JAK1. 
JAK1 is a receptor-associated kinase that phosphorylates and activates STAT3 and is a direct 
target of miR-20a (Doebele et al., 2010). 
In conclusion, we identified a novel IL-6 – miR-17/92 pathway, which, through the miR-18a-
mediated inhibition of PIAS3, enhances IL-6 signaling and, furthermore, represents a novel 
positive feedback loop of this pathway. 
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5.4. Experimental questions (follow-up projects) 
Based on these studies, the following questions are raised and should be addressed by further 
experiments: 
i) which miRNAs have the potency to be used as biomarkers to distinguish onset, 
severity and course of human pulmonary hypertension? 
ii) do these miRNAs have pathogenetic, diagnostic and/ or therapeutic relevance? 
iii) does the inhibition of miRNAs result in a reversal of the vascular remodeling of 
pulmonary arterial vessels? 
iv) is the application of miRNAs a feasible clinical approach to deliver and to 
influence targeted cells? 
v) of what significance are miRNAs in the interplay between inflammation and 
vascular remodeling with special focus on STAT3 and its miRNA-mediated 
feedback loops?  
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7. Abbreviations 
 
BMP     Bone morphogenetic protein 
BMPR2    BMP receptor type II 
ECs      Endothelial cells 
ELISA     Enzyme-linked immunosorbent assay 
FGG      Fibrinogen gamma chain 
GAPDH    Glyceraldehyde-3-phosphate dehydrogenase 
HEK293 cells    Human embryonic kidney cells 
HepG2 cells    Human hepatoma cells 
Hp     Haptoglobin 
HPRT1    Hypoxanthine phosphoribosyltransferase 1 
Id-1 / -2    Inhibitor of DNA binding 1 / -2  
IL-6     Interleukin-6 
JAK     Janus kinase 
miRNA(s)    microRNA(s) 
P(A)H     Pulmonary (arterial) hypertension 
PIAS3     Protein inhibitor of activated STAT, 3 
qPCR     quantitative polymerase chain reaction 
RT-PCR    Reverse transcription-polymerase chain reaction 
SOCS     Suppressor of cytokine signaling 
STAT3    Signal transducer and activator of transcription 3  
SMCs     Smooth muscle cells 
TGF-β     Tumor growth factor β 
TGFBR2    TGF-β receptor type II  
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